{"protocolSection": {"identificationModule": {"nctId": "NCT02414854", "orgStudyIdInfo": {"id": "EFC13579"}, "secondaryIdInfos": [{"id": "2014-004940-36", "type": "EUDRACT_NUMBER"}, {"id": "U1111-1163-1293", "type": "OTHER", "domain": "UTN"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)", "officialTitle": "A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma"}, "statusModule": {"statusVerifiedDate": "2018-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-04-27"}, "primaryCompletionDateStruct": {"date": "2017-07-29", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-11-23", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-04-08", "studyFirstSubmitQcDate": "2015-04-08", "studyFirstPostDateStruct": {"date": "2015-04-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-07-27", "resultsFirstSubmitQcDate": "2018-10-19", "resultsFirstPostDateStruct": {"date": "2018-10-23", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-10-19", "lastUpdatePostDateStruct": {"date": "2018-10-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}, "collaborators": [{"name": "Regeneron Pharmaceuticals", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Primary Objective:\n\nTo evaluate the efficacy of dupilumab (SAR231893 / REGN668) in participants with persistent asthma.\n\nSecondary Objectives:\n\n* To evaluate the safety and tolerability of dupilumab.\n* To evaluate the effect of dupilumab on improving participant-reported outcomes including health-related quality of life.\n* To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies.", "detailedDescription": "The total duration of study period for each participant is 67 to 69 weeks, including a screening period of 3 to 5 weeks, treatment period of 52 weeks, and post-treatment follow-up period of 12 weeks."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1902, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo (for Dupilumab 200 mg) q2w", "type": "PLACEBO_COMPARATOR", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.", "interventionNames": ["Drug: Placebo", "Drug: Inhaled corticosteroid (ICS) therapy", "Drug: Albuterol/Salbutamol", "Drug: Levalbuterol/Levosalbutamol"]}, {"label": "Dupilumab 200 mg q2w", "type": "EXPERIMENTAL", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.", "interventionNames": ["Drug: Dupilumab", "Drug: Inhaled corticosteroid (ICS) therapy", "Drug: Albuterol/Salbutamol", "Drug: Levalbuterol/Levosalbutamol"]}, {"label": "Placebo (for Dupilumab 300 mg) q2w", "type": "PLACEBO_COMPARATOR", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.", "interventionNames": ["Drug: Placebo", "Drug: Inhaled corticosteroid (ICS) therapy", "Drug: Albuterol/Salbutamol", "Drug: Levalbuterol/Levosalbutamol"]}, {"label": "Dupilumab 300 mg q2w", "type": "EXPERIMENTAL", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.", "interventionNames": ["Drug: Dupilumab", "Drug: Inhaled corticosteroid (ICS) therapy", "Drug: Albuterol/Salbutamol", "Drug: Levalbuterol/Levosalbutamol"]}], "interventions": [{"type": "DRUG", "name": "Dupilumab", "description": "Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.", "armGroupLabels": ["Dupilumab 200 mg q2w", "Dupilumab 300 mg q2w"], "otherNames": ["SAR231893", "REGN668"]}, {"type": "DRUG", "name": "Placebo", "description": "Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.", "armGroupLabels": ["Placebo (for Dupilumab 200 mg) q2w", "Placebo (for Dupilumab 300 mg) q2w"]}, {"type": "DRUG", "name": "Inhaled corticosteroid (ICS) therapy", "description": "Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)", "armGroupLabels": ["Dupilumab 200 mg q2w", "Dupilumab 300 mg q2w", "Placebo (for Dupilumab 200 mg) q2w", "Placebo (for Dupilumab 300 mg) q2w"]}, {"type": "DRUG", "name": "Albuterol/Salbutamol", "description": "Oral inhalation as needed", "armGroupLabels": ["Dupilumab 200 mg q2w", "Dupilumab 300 mg q2w", "Placebo (for Dupilumab 200 mg) q2w", "Placebo (for Dupilumab 300 mg) q2w"]}, {"type": "DRUG", "name": "Levalbuterol/Levosalbutamol", "description": "Oral inhalation as needed", "armGroupLabels": ["Dupilumab 200 mg q2w", "Dupilumab 300 mg q2w", "Placebo (for Dupilumab 200 mg) q2w", "Placebo (for Dupilumab 300 mg) q2w"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "timeFrame": "Baseline to Week 52"}, {"measure": "Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Week 12"}], "secondaryOutcomes": [{"measure": "Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Week 12"}, {"measure": "Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "timeFrame": "Baseline to Week 52"}, {"measure": "Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Week 12"}, {"measure": "Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "timeFrame": "Baseline to Week 52"}, {"measure": "Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Week 12"}, {"measure": "Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "timeFrame": "Baseline to Week 52"}, {"measure": "Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "timeFrame": "Baseline to Week 52"}, {"measure": "Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change From Baseline in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ [S]) Self-Administered Global Score at Week 24: ITT Population", "description": "The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in AQLQ (S) Self- Administered Global Score at Week 24: ITT Population With Baseline Eosinophil >=0.3 Giga/L", "description": "The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 24: ITT Population", "description": "The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.", "timeFrame": "Baseline, Week 24"}, {"measure": "Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations (resulted hospitalization or emergency room visit) that occurred during the treatment period divided by the total number of participant-years treated.", "timeFrame": "Baseline to Week 52"}, {"measure": "Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Week 12"}, {"measure": "Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Week 12"}, {"measure": "Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Week 12"}, {"measure": "Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Week 12"}, {"measure": "Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Weeks 2, 4, 8, 24, 36, and 52"}, {"measure": "Percent Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Weeks 2, 4, 8, 24, 36, and 52"}, {"measure": "Change From Baseline in Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52"}, {"measure": "Change From Baseline in Morning (AM)/Evening (PM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52"}, {"measure": "Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters.", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52"}, {"measure": "Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "FEF is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF25-75% is defined as the mean forced expiratory flow between the 25% and 75% of the FVC.", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52"}, {"measure": "Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52"}, {"measure": "Annualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population", "description": "LOAC was defined as any of the following: \\>=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS \\>=4 times the dose at randomization; use of systemic corticosteroids for \\>=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.", "timeFrame": "Baseline to Week 52"}, {"measure": "Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population", "description": "The time to first severe exacerbation was defined as follows: date of the first event - randomization date +1. For participants who had no event on or before Visit 18 (Week 52) or last contact date, the time was censored at the date of Visit 18 or the last contact date, whichever was earlier. The median time to first severe exacerbation was not estimated; therefore, the probability of severe exacerbation at Weeks 12, 24, 36, and 52, are presented as the descriptive statistics.", "timeFrame": "Baseline up to Week 52"}, {"measure": "Time to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population", "description": "The time to first LOAC event was defined as follows: date of the first event - first dose date +1. For participants who had no event on or before last dose date + 14 days or last contact date, the time was censored at the last dose date + 14 days or the last contact date, whichever was earlier.", "timeFrame": "Baseline up to Week 52"}, {"measure": "Change From Baseline in ACQ-5 Score at Weeks 2, 4, 8, 12, 36, and 52: ITT Population", "description": "The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 36, and 52"}, {"measure": "Change From Baseline in Asthma Control Questionnaire 7-item Version (ACQ-7) Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "The ACQ-7 has 7 questions, the first 5 questions assess the most common asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze plus short-acting bronchodilator use, and FEV1 (pre-bronchodilator % predicted). Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). Clinic staff scored the FEV1% predicted on a 7-point scale. The questions were equally weighted and the ACQ-7 total score was mean of the scores of all 7 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52"}, {"measure": "Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0= No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52"}, {"measure": "Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52"}, {"measure": "Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52"}, {"measure": "Change From Baseline in Number of Puffs of Daily Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded daily by the participants in an electronic diary/peak expiratory flow (PEF) meter. In the case that Nebulizer solutions were used as an alternative delivery method, the nebulizer dose was converted to number of puffs as per following conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) corresponds to 4 puffs.", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52"}, {"measure": "Change From Baseline in AQLQ (S) Self-Administered Global Score at Weeks 12, 36, and 52: ITT Population", "description": "The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.", "timeFrame": "Baseline, Weeks 12, 36, and 52"}, {"measure": "Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Weeks 12, 24, 36, and 52: ITT Population", "description": "EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).", "timeFrame": "Baseline, Weeks 12, 24, 36, and 52"}, {"measure": "Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12, 24, 36, and 52: ITT Population", "description": "The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. And the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.", "timeFrame": "Baseline, Weeks 12, 24, 36, and 52"}, {"measure": "Change From Baseline in 22-Item Sino Nasal Outcome Test (SNOT-22) Score at Weeks 12, 24, 36, and 52: ITT Population With Bilateral Nasal Polyposis/Chronic Rhinosinusitis", "description": "The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.", "timeFrame": "Baseline, Weeks 12, 24, 36, and 52"}, {"measure": "Change From Baseline in Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, Ages 12+ (RQLQ[S]+12) Score at Weeks 12, 24, 36, and 52: ITT Population With Comorbid Allergic Rhinitis", "description": "RQLQ(S)+12 is a self-administered questionnaire with standardized activities developed to measure health-related quality of life signs and symptoms that are most problematic in those 12 to 75 years of age, as a result of perennial or seasonal allergic rhinitis. There are 28 items on RQLQ(S) in 7 domains: activities (3 items), sleep (3 items), non-nose/eye symptoms (7 items), practical problems (3 items), nasal symptoms (4 items), eye symptoms (4 items) and emotional (4 items). RQLQ(S)+12 responses are based on 7-point likert scale with responses ranging from 0 (not troubled) to 6 (extremely troubled). Individual items within RQLQ(S)+12 are equally weighted. The overall score is calculated as the mean score of all items. Higher scores indicated more health-related quality of life impairment (lower scores better).", "timeFrame": "Baseline, Weeks 12, 24, 36, and 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n-Adults and adolescent participants with a physician diagnosis of asthma for \u226512 months, based on the Global Initiative for Asthma (GINA) 2014 Guidelines and the following criteria:\n\na) Existing treatment with medium to high dose ICS (\u2265250 mcg of fluticasone propionate twice daily or equipotent ICS daily dosage to a maximum of 2000 mcg/day of fluticasone propionate or equivalent) in combination with a second controller (eg, long-acting beta agonist, leukotriene receptor antagonist) for at least 3 months with a stable dose \u22651 month prior to Visit 1.\n\ni) Note for Japan: for participants aged 18 years and older, ICS must be on \u2265200 mcg of fluticasone propionate twice daily or equivalent; for participants aged 12 to 17 years, ICS must be \u2265100 mcg of fluticasone propionate twice daily or equivalent).\n\nii) Participants requiring a third controller for their asthma will be considered eligible for this study, and it should also be used for at least 3 months with a stable dose \u22651 month prior to Visit 1.\n\nExclusion criteria:\n\n* Participants \\<12 years of age or the minimum legal age for adolescents in the country of the investigative site, whichever is higher (For those countries where local regulations permit enrollment of adults only, participant recruitment will be restricted to those who are \u226518 years of age).\n* Weight is less than 30 kilograms.\n* Chronic obstructive pulmonary disease or other lung diseases (eg, idiopathic pulmonary fibrosis, Churg-Strauss Syndrome, etc) which may impair lung function.\n* A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization due to asthma, or treatment with systemic steroids at any time from 1 month prior to the Screening Visit up to and including the Baseline Visit).\n* Evidence of lung disease(s) other than asthma, either clinical evidence or imaging (Chest X-ray, CT, MRI) within 12 months of Visit 1 or at the screening visit, as per local standard of care.\n* Note for Japan: According to the request from the health authority, chest X-ray should be performed at screening visit if there is no chest imaging (Chest X-ray, computed tomography \\[CT\\], magnetic resonance imaging \\[MRI\\]) available within 3 months prior to screening to exclude participants with suspected active or untreated latent tuberculosis.\n* Current smoker or cessation of smoking within 6 months prior to Visit 1.\n* Previous smoker with a smoking history \\>10 pack-years.\n* Comorbid disease that might interfere with the evaluation of Investigational Medicinal Product.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Sciences & Operations", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Investigational Site Number 840047", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Investigational Site Number 840056", "city": "Flagstaff", "state": "Arizona", "zip": "86001", "country": "United States", "geoPoint": {"lat": 35.19807, "lon": -111.65127}}, {"facility": "Investigational Site Number 840099", "city": "Gilbert", "state": "Arizona", "zip": "85234", "country": "United States", "geoPoint": {"lat": 33.35283, "lon": -111.78903}}, {"facility": "Investigational Site Number 840087", "city": "Scottsdale", "state": "Arizona", "zip": "85251", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "Investigational Site Number 840132", "city": "Little Rock", "state": "Arkansas", "zip": "72209", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Investigational Site Number 840109", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Investigational Site Number 840052", "city": "Costa Mesa", "state": "California", "zip": "92626", "country": "United States", "geoPoint": {"lat": 33.64113, "lon": -117.91867}}, {"facility": "Investigational Site Number 840116", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Investigational Site Number 840045", "city": "Long Beach", "state": "California", "zip": "90720", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Investigational Site Number 840011", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Investigational Site Number 840061", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Investigational Site Number 840097", "city": "Los Angeles", "state": "California", "zip": "90064", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Investigational Site Number 840019", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Investigational Site Number 840125", "city": "Newport Beach", "state": "California", "zip": "92663", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "Investigational Site Number 840041", "city": "North Hollywood", "state": "California", "zip": "91606", "country": "United States", "geoPoint": {"lat": 34.17223, "lon": -118.37897}}, {"facility": "Investigational Site Number 840036", "city": "Redwood City", "state": "California", "zip": "94063", "country": "United States", "geoPoint": {"lat": 37.48522, "lon": -122.23635}}, {"facility": "Investigational Site Number 840020", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Investigational Site Number 840074", "city": "Roseville", "state": "California", "zip": "95661", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"facility": "Investigational Site Number 840021", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Investigational Site Number 840004", "city": "Centennial", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Investigational Site Number 840025", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Investigational Site Number 840034", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Investigational Site Number 840130", "city": "Denver", "state": "Colorado", "zip": "80246", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Investigational Site Number 840102", "city": "New Haven", "state": "Connecticut", "zip": "06504", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Investigational Site Number 840037", "city": "Aventura", "state": "Florida", "zip": "33180", "country": "United States", "geoPoint": {"lat": 25.95648, "lon": -80.13921}}, {"facility": "Investigational Site Number 840018", "city": "Boynton Beach", "state": "Florida", "zip": "33472", "country": "United States", "geoPoint": {"lat": 26.52535, "lon": -80.06643}}, {"facility": "Investigational Site Number 840105", "city": "Brandon", "state": "Florida", "zip": "33511", "country": "United States", "geoPoint": {"lat": 27.9378, "lon": -82.28592}}, {"facility": "Investigational Site Number 840092", "city": "Clearwater", "state": "Florida", "zip": "33765", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Investigational Site Number 840122", "city": "Hialeah", "state": "Florida", "zip": "33012", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Investigational Site Number 840053", "city": "Loxahatchee Groves", "state": "Florida", "zip": "33470", "country": "United States", "geoPoint": {"lat": 26.68368, "lon": -80.27977}}, {"facility": "Investigational Site Number 840069", "city": "Miami", "state": "Florida", "zip": "33173", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Investigational Site Number 840123", "city": "Ocala", "state": "Florida", "zip": "34471", "country": "United States", "geoPoint": {"lat": 29.1872, "lon": -82.14009}}, {"facility": "Investigational Site Number 840071", "city": "Ocala", "state": "Florida", "zip": "34474", "country": "United States", "geoPoint": {"lat": 29.1872, "lon": -82.14009}}, {"facility": "Investigational Site Number 840115", "city": "Ocoee", "state": "Florida", "zip": "34761", "country": "United States", "geoPoint": {"lat": 28.56917, "lon": -81.54396}}, {"facility": "Investigational Site Number 840055", "city": "Sarasota", "state": "Florida", "zip": "34239", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Investigational Site Number 840114", "city": "South Miami", "state": "Florida", "zip": "33143", "country": "United States", "geoPoint": {"lat": 25.7076, "lon": -80.29338}}, {"facility": "Investigational Site Number 840048", "city": "Tampa", "state": "Florida", "zip": "33612", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Investigational Site Number 840084", "city": "Gainesville", "state": "Georgia", "zip": "30506", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Investigational Site Number 840044", "city": "Savannah", "state": "Georgia", "zip": "31406", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Investigational Site Number 840079", "city": "Twin Falls", "state": "Idaho", "zip": "83301", "country": "United States", "geoPoint": {"lat": 42.56297, "lon": -114.46087}}, {"facility": "Investigational Site Number 840101", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Investigational Site Number 840015", "city": "River Forest", "state": "Illinois", "zip": "60305", "country": "United States", "geoPoint": {"lat": 41.89781, "lon": -87.81395}}, {"facility": "Investigational Site Number 840089", "city": "Iowa City", "state": "Iowa", "zip": "52242", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "Investigational Site Number 840032", "city": "Fort Mitchell", "state": "Kentucky", "zip": "41017", "country": "United States", "geoPoint": {"lat": 39.0595, "lon": -84.54744}}, {"facility": "Investigational Site Number 840009", "city": "Owensboro", "state": "Kentucky", "zip": "42303", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "Investigational Site Number 840064", "city": "Bangor", "state": "Maine", "zip": "04401", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Investigational Site Number 840080", "city": "Baltimore", "state": "Maryland", "zip": "21237", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Investigational Site Number 840017", "city": "Chevy Chase", "state": "Maryland", "zip": "20815", "country": "United States", "geoPoint": {"lat": 39.00287, "lon": -77.07115}}, {"facility": "Investigational Site Number 840073", "city": "Gaithersburg", "state": "Maryland", "zip": "20878", "country": "United States", "geoPoint": {"lat": 39.14344, "lon": -77.20137}}, {"facility": "Investigational Site Number 840127", "city": "White Marsh", "state": "Maryland", "zip": "21162", "country": "United States", "geoPoint": {"lat": 39.38372, "lon": -76.43218}}, {"facility": "Investigational Site Number 840014", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Investigational Site Number 840005", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Investigational Site Number 840013", "city": "Kansas City", "state": "Missouri", "zip": "64111", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Investigational Site Number 840002", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Investigational Site Number 840093", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Investigational Site Number 840026", "city": "Missoula", "state": "Montana", "zip": "59808", "country": "United States", "geoPoint": {"lat": 46.87215, "lon": -113.994}}, {"facility": "Investigational Site Number 840078", "city": "Omaha", "state": "Nebraska", "zip": "68131", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Investigational Site Number 840003", "city": "Papillion", "state": "Nebraska", "zip": "27103", "country": "United States", "geoPoint": {"lat": 41.15444, "lon": -96.04224}}, {"facility": "Investigational Site Number 840111", "city": "Brick", "state": "New Jersey", "zip": "08723", "country": "United States", "geoPoint": {"lat": 40.05928, "lon": -74.13708}}, {"facility": "Investigational Site Number 840068", "city": "Ocean City", "state": "New Jersey", "zip": "07712", "country": "United States", "geoPoint": {"lat": 39.27762, "lon": -74.5746}}, {"facility": "Investigational Site Number 840016", "city": "Princeton", "state": "New Jersey", "zip": "08540", "country": "United States", "geoPoint": {"lat": 40.34872, "lon": -74.65905}}, {"facility": "Investigational Site Number 840096", "city": "Toms River", "state": "New Jersey", "zip": "08775", "country": "United States", "geoPoint": {"lat": 39.95373, "lon": -74.19792}}, {"facility": "Investigational Site Number 840031", "city": "Bronx", "state": "New York", "zip": "10457", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Investigational Site Number 840106", "city": "Jamaica", "state": "New York", "zip": "11435", "country": "United States", "geoPoint": {"lat": 40.69149, "lon": -73.80569}}, {"facility": "Investigational Site Number 840065", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Investigational Site Number 840076", "city": "Rochester", "state": "New York", "zip": "14642", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "Investigational Site Number 840126", "city": "Charlotte", "state": "North Carolina", "zip": "28226", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Investigational Site Number 840083", "city": "Charlotte", "state": "North Carolina", "zip": "28277", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Investigational Site Number 840108", "city": "Durham", "state": "North Carolina", "zip": "27705", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Investigational Site Number 840107", "city": "Greensboro", "state": "North Carolina", "zip": "27403", "country": "United States", "geoPoint": {"lat": 36.07264, "lon": -79.79198}}, {"facility": "Investigational Site Number 840007", "city": "High Point", "state": "North Carolina", "zip": "27262", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Investigational Site Number 840046", "city": "Cincinnati", "state": "Ohio", "zip": "45241", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Investigational Site Number 840049", "city": "Middleburg Heights", "state": "Ohio", "zip": "44130", "country": "United States", "geoPoint": {"lat": 41.36144, "lon": -81.81291}}, {"facility": "Investigational Site Number 840042", "city": "Toledo", "state": "Ohio", "zip": "43617", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Investigational Site Number 840112", "city": "Edmond", "state": "Oklahoma", "zip": "73034", "country": "United States", "geoPoint": {"lat": 35.65283, "lon": -97.4781}}, {"facility": "Investigational Site Number 840121", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Investigational Site Number 840104", "city": "Tulsa", "state": "Oklahoma", "zip": "74136", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Investigational Site Number 840040", "city": "Clackamas", "state": "Oregon", "zip": "97015", "country": "United States", "geoPoint": {"lat": 45.40762, "lon": -122.57037}}, {"facility": "Investigational Site Number 840039", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Investigational Site Number 840001", "city": "Portland", "state": "Oregon", "zip": "97223", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Investigational Site Number 840085", "city": "Hershey", "state": "Pennsylvania", "zip": "17033", "country": "United States", "geoPoint": {"lat": 40.28592, "lon": -76.65025}}, {"facility": "Investigational Site Number 840081", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19102", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Investigational Site Number 840010", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19107", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Investigational Site Number 840067", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Investigational Site Number 840028", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Investigational Site Number 840091", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15241", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Investigational Site Number 840029", "city": "Lincoln", "state": "Rhode Island", "zip": "02286", "country": "United States", "geoPoint": {"lat": 41.92111, "lon": -71.435}}, {"facility": "Investigational Site Number 840082", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Investigational Site Number 840117", "city": "Greenville", "state": "South Carolina", "zip": "29607", "country": "United States", "geoPoint": {"lat": 34.85262, "lon": -82.39401}}, {"facility": "Investigational Site Number 840100", "city": "Greer", "state": "South Carolina", "zip": "29651", "country": "United States", "geoPoint": {"lat": 34.93873, "lon": -82.22706}}, {"facility": "Investigational Site Number 840054", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Investigational Site Number 840062", "city": "Amarillo", "state": "Texas", "zip": "79106", "country": "United States", "geoPoint": {"lat": 35.222, "lon": -101.8313}}, {"facility": "Investigational Site Number 840098", "city": "Austin", "state": "Texas", "zip": "78759", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Investigational Site Number 840038", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Investigational Site Number 840124", "city": "Cypress", "state": "Texas", "zip": "77429", "country": "United States", "geoPoint": {"lat": 29.96911, "lon": -95.69717}}, {"facility": "Investigational Site Number 840008", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Investigational Site Number 840094", "city": "Dallas", "state": "Texas", "zip": "75246", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Investigational Site Number 840023", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Investigational Site Number 840022", "city": "Fort Worth", "state": "Texas", "zip": "76109", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Investigational Site Number 840027", "city": "Fort Worth", "state": "Texas", "zip": "76244", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Investigational Site Number 840066", "city": "Killeen", "state": "Texas", "zip": "76542", "country": "United States", "geoPoint": {"lat": 31.11712, "lon": -97.7278}}, {"facility": "Investigational Site Number 840050", "city": "Live Oak", "state": "Texas", "zip": "78233", "country": "United States", "geoPoint": {"lat": 29.56523, "lon": -98.3364}}, {"facility": "Investigational Site Number 840070", "city": "McKinney", "state": "Texas", "zip": "75069", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Investigational Site Number 840128", "city": "McKinney", "state": "Texas", "zip": "75071", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Investigational Site Number 840118", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Investigational Site Number 840012", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Investigational Site Number 840129", "city": "San Antonio", "state": "Texas", "zip": "78251", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Investigational Site Number 840133", "city": "Sealy", "state": "Texas", "zip": "77474", "country": "United States", "geoPoint": {"lat": 29.78079, "lon": -96.15718}}, {"facility": "Investigational Site Number 840119", "city": "Spring", "state": "Texas", "zip": "77380", "country": "United States", "geoPoint": {"lat": 30.07994, "lon": -95.41716}}, {"facility": "Investigational Site Number 840035", "city": "Draper", "state": "Utah", "zip": "84020", "country": "United States", "geoPoint": {"lat": 40.52467, "lon": -111.86382}}, {"facility": "Investigational Site Number 840077", "city": "Murray", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "Investigational Site Number 840057", "city": "South Burlington", "state": "Vermont", "zip": "05403", "country": "United States", "geoPoint": {"lat": 44.46699, "lon": -73.17096}}, {"facility": "Investigational Site Number 840059", "city": "Fairfax", "state": "Virginia", "zip": "22030", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "Investigational Site Number 840113", "city": "Richmond", "state": "Virginia", "zip": "23294", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Investigational Site Number 840051", "city": "Bellevue", "state": "Washington", "zip": "98225", "country": "United States", "geoPoint": {"lat": 47.61038, "lon": -122.20068}}, {"facility": "Investigational Site Number 840043", "city": "Spokane", "state": "Washington", "zip": "99202", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Investigational Site Number 032006", "city": "Bahia Blanca", "zip": "B8000JRB", "country": "Argentina", "geoPoint": {"lat": -38.71959, "lon": -62.27243}}, {"facility": "Investigational Site Number 032002", "city": "Buenos Aires", "zip": "C1121ABE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032011", "city": "Caba", "zip": "1120", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032007", "city": "Caba", "zip": "C1414AIF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032001", "city": "Caba", "zip": "C1425BEN", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032003", "city": "Caba", "zip": "C1425FVH", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032010", "city": "Caba", "zip": "C1426ABP", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032005", "city": "Capital Federal", "zip": "C1425DUC", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Investigational Site Number 032008", "city": "La Plata", "zip": "B1900DXM", "country": "Argentina", "geoPoint": {"lat": -34.92145, "lon": -57.95453}}, {"facility": "Investigational Site Number 032004", "city": "Rosario", "zip": "S2000JKR", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Investigational Site Number 032012", "city": "San Miguel De Tucuman", "zip": "T4000CHE", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Investigational Site Number 032009", "city": "San Miguel De Tucum\u00e1n", "zip": "T4000IAR", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Investigational Site Number 036005", "city": "Campbelltown", "zip": "2560", "country": "Australia", "geoPoint": {"lat": -34.06667, "lon": 150.81667}}, {"facility": "Investigational Site Number 036001", "city": "Clayton", "zip": "3168", "country": "Australia", "geoPoint": {"lat": -37.91667, "lon": 145.11667}}, {"facility": "Investigational Site Number 036002", "city": "Frankston", "zip": "3199", "country": "Australia", "geoPoint": {"lat": -38.14458, "lon": 145.12291}}, {"facility": "Investigational Site Number 036006", "city": "Glen Osmond", "zip": "5064", "country": "Australia", "geoPoint": {"lat": -34.9596, "lon": 138.64873}}, {"facility": "Investigational Site Number 036003", "city": "Murdoch", "zip": "6150", "country": "Australia", "geoPoint": {"lat": -32.06987, "lon": 115.83757}}, {"facility": "Investigational Site Number 036004", "city": "Parkville", "zip": "3050", "country": "Australia", "geoPoint": {"lat": -37.78333, "lon": 144.95}}, {"facility": "Investigational Site Number 076009", "city": "Florian\u00f3polis", "zip": "88040-970", "country": "Brazil", "geoPoint": {"lat": -27.59667, "lon": -48.54917}}, {"facility": "Investigational Site Number 076007", "city": "Porto Alegre", "zip": "90020-090", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Investigational Site Number 076001", "city": "Porto Alegre", "zip": "90610-000", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Investigational Site Number 076003", "city": "Salvador", "zip": "41940-455", "country": "Brazil", "geoPoint": {"lat": -12.97111, "lon": -38.51083}}, {"facility": "Investigational Site Number 076012", "city": "Sao Paulo", "zip": "04266-010", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Investigational Site Number 076008", "city": "Sao Paulo", "zip": "05403-000", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Investigational Site Number 076006", "city": "Sao Paulo", "zip": "05437-010", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Investigational Site Number 076002", "city": "Sorocaba", "zip": "18040-425", "country": "Brazil", "geoPoint": {"lat": -23.50167, "lon": -47.45806}}, {"facility": "Investigational Site Number 076013", "city": "S\u00e3o Bernardo Do Campo", "zip": "09715-090", "country": "Brazil", "geoPoint": {"lat": -23.69389, "lon": -46.565}}, {"facility": "Investigational Site Number 124019", "city": "Burlington", "zip": "L7N 3V2", "country": "Canada", "geoPoint": {"lat": 43.38621, "lon": -79.83713}}, {"facility": "Investigational Site Number 124009", "city": "Calgary", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Investigational Site Number 124003", "city": "Mississauga", "zip": "L5A 3V4", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "Investigational Site Number 124001", "city": "Montreal", "zip": "H2W 1T8", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Investigational Site Number 124012", "city": "Montreal", "zip": "H4A 3J1", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Investigational Site Number 124010", "city": "Montreal", "zip": "H4J 1C5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Investigational Site Number 124013", "city": "Ottawa", "zip": "K1G 6C6", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Investigational Site Number 124018", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Investigational Site Number 124014", "city": "Quebec", "zip": "G1V 4W2", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Investigational Site Number 124008", "city": "Sherbrooke", "zip": "J1H 5N4", "country": "Canada", "geoPoint": {"lat": 45.40008, "lon": -71.89908}}, {"facility": "Investigational Site Number 124015", "city": "Toronto", "zip": "M5G 1E2", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Investigational Site Number 124002", "city": "Toronto", "zip": "M5T 3A9", "country": "Canada", "geoPoint": {"lat": 43.70011, "lon": -79.4163}}, {"facility": "Investigational Site Number 124007", "city": "Trois-Rivieres", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Investigational Site Number 124006", "city": "Vancouver", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Investigational Site Number 152015", "city": "Concepci\u00f3n", "zip": "41", "country": "Chile", "geoPoint": {"lat": -36.82699, "lon": -73.04977}}, {"facility": "Investigational Site Number 152003", "city": "Quillota", "zip": "2260877", "country": "Chile", "geoPoint": {"lat": -32.88341, "lon": -71.24882}}, {"facility": "Investigational Site Number 152014", "city": "Santiago", "zip": "7500588", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152001", "city": "Santiago", "zip": "7500692", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152002", "city": "Santiago", "zip": "7500698", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152008", "city": "Santiago", "zip": "7500710", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152017", "city": "Santiago", "zip": "7560994", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152007", "city": "Santiago", "zip": "8207257", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152005", "city": "Santiago", "zip": "8380456", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152009", "city": "Santiago", "zip": "8910131", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Investigational Site Number 152013", "city": "Talcahuano", "zip": "427918", "country": "Chile", "geoPoint": {"lat": -36.72494, "lon": -73.11684}}, {"facility": "Investigational Site Number 152004", "city": "Talca", "zip": "3460001", "country": "Chile", "geoPoint": {"lat": -35.4264, "lon": -71.65542}}, {"facility": "Investigational Site Number 152016", "city": "Temuco", "zip": "4781156", "country": "Chile", "geoPoint": {"lat": -38.73965, "lon": -72.59842}}, {"facility": "Investigational Site Number 152010", "city": "Valdivia", "country": "Chile", "geoPoint": {"lat": -39.81422, "lon": -73.24589}}, {"facility": "Investigational Site Number 152011", "city": "Vi\u00f1a Del Mar", "zip": "2520594", "country": "Chile", "geoPoint": {"lat": -33.02457, "lon": -71.55183}}, {"facility": "Investigational Site Number 152012", "city": "Vi\u00f1a Del Mar", "country": "Chile", "geoPoint": {"lat": -33.02457, "lon": -71.55183}}, {"facility": "Investigational Site Number 170006", "city": "Bogota", "zip": "110131", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Investigational Site Number 170001", "city": "Bogota", "zip": "110221", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Investigational Site Number 170002", "city": "Bogot\u00e1", "zip": "110231", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Investigational Site Number 170003", "city": "Bogot\u00e1", "zip": "111321", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Investigational Site Number 250002", "city": "Brest", "zip": "29609", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Investigational Site Number 250011", "city": "Lille Cedex", "zip": "59037", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"facility": "Investigational Site Number 250013", "city": "Lille", "zip": "59000", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"facility": "Investigational Site Number 250004", "city": "Lyon", "zip": "69317", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "Investigational Site Number 250010", "city": "Marseille", "zip": "13015", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Investigational Site Number 250005", "city": "Montpellier", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Investigational Site Number 250003", "city": "Nantes Cedex 1", "zip": "44093", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "Investigational Site Number 250012", "city": "Paris", "zip": "75012", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Investigational Site Number 250001", "city": "Paris", "zip": "75018", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Investigational Site Number 250008", "city": "Strasbourg", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Investigational Site Number 250014", "city": "Vandoeuvre-Les-Nancy", "zip": "54511", "country": "France", "geoPoint": {"lat": 48.65, "lon": 6.18333}}, {"facility": "Investigational Site Number 276006", "city": "Berlin", "zip": "10787", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Investigational Site Number 276003", "city": "Bochum", "zip": "44789", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "Investigational Site Number 276010", "city": "Frankfurt Am Main", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Investigational Site Number 276004", "city": "Hannover", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Investigational Site Number 276009", "city": "Koblenz", "zip": "56068", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "Investigational Site Number 276007", "city": "L\u00fcbeck", "zip": "23538", "country": "Germany", "geoPoint": {"lat": 53.86893, "lon": 10.68729}}, {"facility": "Investigational Site Number 276001", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Investigational Site Number 276005", "city": "R\u00fcdersdorf", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "Investigational Site Number 348003", "city": "G\u00f6d\u00f6ll\u00f6", "zip": "2100", "country": "Hungary", "geoPoint": {"lat": 47.59657, "lon": 19.35515}}, {"facility": "Investigational Site Number 380004", "city": "Ancona", "zip": "60126", "country": "Italy", "geoPoint": {"lat": 43.5942, "lon": 13.50337}}, {"facility": "Investigational Site Number 380005", "city": "Catania", "zip": "95123", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Investigational Site Number 380003", "city": "Ferrara", "zip": "44124", "country": "Italy", "geoPoint": {"lat": 44.83804, "lon": 11.62057}}, {"facility": "Investigational Site Number 380006", "city": "Firenze", "zip": "50134", "country": "Italy", "geoPoint": {"lat": 43.77925, "lon": 11.24626}}, {"facility": "Investigational Site Number 380010", "city": "Foggia", "zip": "71122", "country": "Italy", "geoPoint": {"lat": 41.45845, "lon": 15.55188}}, {"facility": "Investigational Site Number 380002", "city": "Modena", "zip": "41124", "country": "Italy", "geoPoint": {"lat": 44.64783, "lon": 10.92539}}, {"facility": "Investigational Site Number 380009", "city": "Palermo", "zip": "90146", "country": "Italy", "geoPoint": {"lat": 38.13205, "lon": 13.33561}}, {"facility": "Investigational Site Number 380001", "city": "Pisa", "zip": "56124", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "Investigational Site Number 380014", "city": "Reggio Emilia", "zip": "42123", "country": "Italy", "geoPoint": {"lat": 44.69825, "lon": 10.63125}}, {"facility": "Investigational Site Number 380011", "city": "Torino", "zip": "10128", "country": "Italy", "geoPoint": {"lat": 45.07049, "lon": 7.68682}}, {"facility": "Investigational Site Number 392185", "city": "Akashi-Shi", "country": "Japan", "geoPoint": {"lat": 34.65522, "lon": 135.00687}}, {"facility": "Investigational Site Number 392128", "city": "Asahikawa-Shi", "country": "Japan", "geoPoint": {"lat": 43.77063, "lon": 142.36489}}, {"facility": "Investigational Site Number 392118", "city": "Chiyoda-Ku", "country": "Japan"}, {"facility": "Investigational Site Number 392112", "city": "Chuo-Ku", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Investigational Site Number 392157", "city": "Fukui-Shi", "country": "Japan", "geoPoint": {"lat": 36.06443, "lon": 136.22257}}, {"facility": "Investigational Site Number 392137", "city": "Fukuoka-Shi", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Investigational Site Number 392117", "city": "Fukuyama-Shi", "country": "Japan", "geoPoint": {"lat": 34.48333, "lon": 133.36667}}, {"facility": "Investigational Site Number 392121", "city": "Habikino-Shi", "country": "Japan", "geoPoint": {"lat": 34.55276, "lon": 135.59097}}, {"facility": "Investigational Site Number 392154", "city": "Higashiosaka-Shi", "country": "Japan", "geoPoint": {"lat": 34.66667, "lon": 135.58333}}, {"facility": "Investigational Site Number 392109", "city": "Himeji-Shi", "country": "Japan", "geoPoint": {"lat": 34.81667, "lon": 134.7}}, {"facility": "Investigational Site Number 392108", "city": "Hiroshima-Shi", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Investigational Site Number 392158", "city": "Hiroshima-Shi", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "Investigational Site Number 392107", "city": "Iizuka-Shi", "country": "Japan", "geoPoint": {"lat": 33.63654, "lon": 130.68678}}, {"facility": "Investigational Site Number 392101", "city": "Isesaki-Shi", "country": "Japan", "geoPoint": {"lat": 36.31667, "lon": 139.2}}, {"facility": "Investigational Site Number 392147", "city": "Itabashi-Ku", "country": "Japan", "geoPoint": {"lat": 35.74893, "lon": 139.71497}}, {"facility": "Investigational Site Number 392150", "city": "Kagoshima-Shi", "country": "Japan", "geoPoint": {"lat": 31.56667, "lon": 130.55}}, {"facility": "Investigational Site Number 392178", "city": "Kagoshima-Shi", "country": "Japan", "geoPoint": {"lat": 31.56667, "lon": 130.55}}, {"facility": "Investigational Site Number 392110", "city": "Kanazawa-Shi", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 136.61667}}, {"facility": "Investigational Site Number 392136", "city": "Kanazawa-Shi", "country": "Japan", "geoPoint": {"lat": 36.6, "lon": 136.61667}}, {"facility": "Investigational Site Number 392142", "city": "Kasuga-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392166", "city": "Kawaguchi-Shi", "country": "Japan", "geoPoint": {"lat": 35.80521, "lon": 139.71072}}, {"facility": "Investigational Site Number 392119", "city": "Kishiwada-Shi", "country": "Japan", "geoPoint": {"lat": 34.46667, "lon": 135.36667}}, {"facility": "Investigational Site Number 392162", "city": "Kobe-Shi", "country": "Japan", "geoPoint": {"lat": 34.6913, "lon": 135.183}}, {"facility": "Investigational Site Number 392182", "city": "Kodaira-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392174", "city": "Kokubunji-Shi", "country": "Japan", "geoPoint": {"lat": 35.70222, "lon": 139.47556}}, {"facility": "Investigational Site Number 392131", "city": "Koshi-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392183", "city": "Koshigaya-Shi", "country": "Japan", "geoPoint": {"lat": 35.89035, "lon": 139.78916}}, {"facility": "Investigational Site Number 392129", "city": "Kurashiki-Shi", "country": "Japan", "geoPoint": {"lat": 34.58333, "lon": 133.76667}}, {"facility": "Investigational Site Number 392153", "city": "Kyoto-Shi", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Investigational Site Number 392176", "city": "Kyoto-Shi", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Investigational Site Number 392184", "city": "Kyoto-Shi", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "Investigational Site Number 392133", "city": "Machida-Shi", "country": "Japan", "geoPoint": {"lat": 35.54028, "lon": 139.45083}}, {"facility": "Investigational Site Number 392135", "city": "Matsuyama-Shi", "country": "Japan", "geoPoint": {"lat": 33.83916, "lon": 132.76574}}, {"facility": "Investigational Site Number 392172", "city": "Mibu", "country": "Japan", "geoPoint": {"lat": 36.41667, "lon": 139.8}}, {"facility": "Investigational Site Number 392114", "city": "Minato-Ku", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Investigational Site Number 392122", "city": "Minato-Ku", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Investigational Site Number 392144", "city": "Minato-Ku", "country": "Japan", "geoPoint": {"lat": 34.2152, "lon": 135.1501}}, {"facility": "Investigational Site Number 392106", "city": "Mizunami-Shi", "country": "Japan", "geoPoint": {"lat": 35.36667, "lon": 137.25}}, {"facility": "Investigational Site Number 392164", "city": "Muroran-Shi", "country": "Japan", "geoPoint": {"lat": 42.31722, "lon": 140.98806}}, {"facility": "Investigational Site Number 392161", "city": "Nagakute-Shi", "country": "Japan", "geoPoint": {"lat": 35.17325, "lon": 137.05667}}, {"facility": "Investigational Site Number 392163", "city": "Nagoya-Shi", "country": "Japan", "geoPoint": {"lat": 35.18147, "lon": 136.90641}}, {"facility": "Investigational Site Number 392102", "city": "Naka-Gun", "country": "Japan", "geoPoint": {"lat": 36.05, "lon": 140.16667}}, {"facility": "Investigational Site Number 392125", "city": "Nakano-Ku", "country": "Japan", "geoPoint": {"lat": 36.75, "lon": 138.36667}}, {"facility": "Investigational Site Number 392115", "city": "Naruto-Shi", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.41667}}, {"facility": "Investigational Site Number 392187", "city": "Obihiro-Shi", "country": "Japan", "geoPoint": {"lat": 42.91722, "lon": 143.20444}}, {"facility": "Investigational Site Number 392177", "city": "Ome-Shi", "country": "Japan", "geoPoint": {"lat": 35.78389, "lon": 139.24306}}, {"facility": "Investigational Site Number 392152", "city": "Osaka Sayama-Shi", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Investigational Site Number 392155", "city": "Osaka Sayama-Shi", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Investigational Site Number 392170", "city": "Osaki-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392120", "city": "Ota-Ku", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Investigational Site Number 392127", "city": "Ota-Ku", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Investigational Site Number 392138", "city": "Ota-Shi", "country": "Japan", "geoPoint": {"lat": 36.3, "lon": 139.36667}}, {"facility": "Investigational Site Number 392123", "city": "Oura-Gun", "country": "Japan"}, {"facility": "Investigational Site Number 392169", "city": "Sagamihara-Shi", "country": "Japan", "geoPoint": {"lat": 35.54899, "lon": 139.26064}}, {"facility": "Investigational Site Number 392149", "city": "Sapporo-Shi", "country": "Japan", "geoPoint": {"lat": 43.06667, "lon": 141.35}}, {"facility": "Investigational Site Number 392179", "city": "Seto-Shi", "country": "Japan", "geoPoint": {"lat": 35.23333, "lon": 137.1}}, {"facility": "Investigational Site Number 392186", "city": "Shibuya-Ku", "country": "Japan", "geoPoint": {"lat": 35.469, "lon": 140.29807}}, {"facility": "Investigational Site Number 392139", "city": "Shinagawa-Ku", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Investigational Site Number 392167", "city": "Shinagawa-Ku", "country": "Japan", "geoPoint": {"lat": 33.63627, "lon": 133.00572}}, {"facility": "Investigational Site Number 392130", "city": "Shinjuku-Ku", "country": "Japan", "geoPoint": {"lat": 35.2946, "lon": 139.57059}}, {"facility": "Investigational Site Number 392165", "city": "Sumida-Ku", "country": "Japan"}, {"facility": "Investigational Site Number 392146", "city": "Tachikawa-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392173", "city": "Tachikawa-Shi", "country": "Japan"}, {"facility": "Investigational Site Number 392103", "city": "Tokyo", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "Investigational Site Number 392113", "city": "Tomakomai-Shi", "country": "Japan", "geoPoint": {"lat": 42.63694, "lon": 141.60333}}, {"facility": "Investigational Site Number 392151", "city": "Tsu-Shi", "country": "Japan", "geoPoint": {"lat": 34.73333, "lon": 136.51667}}, {"facility": "Investigational Site Number 392168", "city": "Uozu-Shi", "country": "Japan", "geoPoint": {"lat": 36.8, "lon": 137.4}}, {"facility": "Investigational Site Number 392132", "city": "Urasoe-Shi", "country": "Japan", "geoPoint": {"lat": 26.25902, "lon": 127.73012}}, {"facility": "Investigational Site Number 392134", "city": "Uruma-Shi", "country": "Japan", "geoPoint": {"lat": 26.37609, "lon": 127.85908}}, {"facility": "Investigational Site Number 392116", "city": "Wakayama-Shi", "country": "Japan", "geoPoint": {"lat": 34.23333, "lon": 135.16667}}, {"facility": "Investigational Site Number 392140", "city": "Yokohama-Shi", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 139.65}}, {"facility": "Investigational Site Number 392159", "city": "Yonago-Shi", "country": "Japan", "geoPoint": {"lat": 35.43333, "lon": 133.33333}}, {"facility": "Investigational Site Number 410002", "city": "Bucheon-Si", "zip": "14584", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Investigational Site Number 410015", "city": "Busan", "zip": "49201", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Investigational Site Number 410003", "city": "Cheongju-Si", "zip": "28644", "country": "Korea, Republic of", "geoPoint": {"lat": 36.63722, "lon": 127.48972}}, {"facility": "Investigational Site Number 410013", "city": "Incheon", "zip": "21565", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "Investigational Site Number 410008", "city": "Seoul", "zip": "02559", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410006", "city": "Seoul", "zip": "03080", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410004", "city": "Seoul", "zip": "03722", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410012", "city": "Seoul", "zip": "04763", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410005", "city": "Seoul", "zip": "05505", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410007", "city": "Seoul", "zip": "06351", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410009", "city": "Seoul", "zip": "06591", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410010", "city": "Seoul", "zip": "06973", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410011", "city": "Seoul", "zip": "08308", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Investigational Site Number 410001", "city": "Suwon", "zip": "16499", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Investigational Site Number 410014", "city": "Uijeongbu-Si", "zip": "11765", "country": "Korea, Republic of", "geoPoint": {"lat": 37.7415, "lon": 127.0474}}, {"facility": "Investigational Site Number 484013", "city": "Chihuahua", "zip": "31020", "country": "Mexico", "geoPoint": {"lat": 28.63528, "lon": -106.08889}}, {"facility": "Investigational Site Number 484006", "city": "Chihuahua", "zip": "31200", "country": "Mexico", "geoPoint": {"lat": 28.63528, "lon": -106.08889}}, {"facility": "Investigational Site Number 484014", "city": "Cuautitlan Izcalli", "zip": "54769", "country": "Mexico", "geoPoint": {"lat": 19.64388, "lon": -99.21598}}, {"facility": "Investigational Site Number 484008", "city": "Durango", "zip": "34080", "country": "Mexico", "geoPoint": {"lat": 24.02032, "lon": -104.65756}}, {"facility": "Investigational Site Number 484001", "city": "Guadalajara", "zip": "44100", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Investigational Site Number 484004", "city": "Mexico City", "zip": "64718", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Investigational Site Number 484003", "city": "Monterrey", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Investigational Site Number 484007", "city": "Monterrey", "zip": "66465", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Investigational Site Number 484010", "city": "M\u00e9xico", "zip": "06700", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Investigational Site Number 484012", "city": "San Juan Del Rio", "zip": "76800", "country": "Mexico", "geoPoint": {"lat": 20.38886, "lon": -99.99577}}, {"facility": "Investigational Site Number 484011", "city": "Veracruz", "zip": "91910", "country": "Mexico", "geoPoint": {"lat": 19.18095, "lon": -96.1429}}, {"facility": "Investigational Site Number 484015", "city": "Zapopan", "zip": "45100", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "Investigational Site Number 616006", "city": "Bialystok", "zip": "15-010", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Investigational Site Number 616003", "city": "Gdansk", "zip": "80-952", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "Investigational Site Number 616007", "city": "Krakow", "zip": "31-159", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Investigational Site Number 616001", "city": "Lodz", "zip": "90-141", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Investigational Site Number 616005", "city": "Lodz", "zip": "90-153", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Investigational Site Number 616009", "city": "Lodz", "zip": "90-329", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Investigational Site Number 616002", "city": "Poznan", "zip": "60-693", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Investigational Site Number 616004", "city": "Sopot", "zip": "81-741", "country": "Poland", "geoPoint": {"lat": 54.4418, "lon": 18.56003}}, {"facility": "Investigational Site Number 616008", "city": "Strzelce Opolskie", "zip": "47-100", "country": "Poland", "geoPoint": {"lat": 50.5107, "lon": 18.30056}}, {"facility": "Investigational Site Number 643013", "city": "Ekaterinburg", "zip": "620109", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"facility": "Investigational Site Number 643006", "city": "Moscow", "zip": "105077", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643003", "city": "Moscow", "zip": "109240", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643005", "city": "Moscow", "zip": "115280", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643002", "city": "Moscow", "zip": "117574", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643004", "city": "Moscow", "zip": "123182", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643001", "city": "Moscow", "zip": "125315", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Investigational Site Number 643011", "city": "Ryazan", "zip": "390039", "country": "Russian Federation", "geoPoint": {"lat": 54.6269, "lon": 39.6916}}, {"facility": "Investigational Site Number 643008", "city": "Saint-Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643009", "city": "Saint-Petersburg", "zip": "195030", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643007", "city": "St-Petersburg", "zip": "193231", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643010", "city": "St-Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Investigational Site Number 643012", "city": "Yaroslavl", "zip": "150003", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Investigational Site Number 710009", "city": "Brandfort", "zip": "9400", "country": "South Africa", "geoPoint": {"lat": -28.70008, "lon": 26.45968}}, {"facility": "Investigational Site Number 710011", "city": "Cape Town", "zip": "7505", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710004", "city": "Cape Town", "zip": "7530", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710001", "city": "Cape Town", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710002", "city": "Cape Town", "zip": "7700", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710010", "city": "Cape Town", "zip": "7764", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710003", "city": "Cape Town", "zip": "8000", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Investigational Site Number 710005", "city": "Durban", "zip": "4001", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Investigational Site Number 710006", "city": "Durban", "zip": "4071", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Investigational Site Number 710007", "city": "Pretoria", "zip": "0087", "country": "South Africa", "geoPoint": {"lat": -25.74486, "lon": 28.18783}}, {"facility": "Investigational Site Number 724002", "city": "Barcelona", "zip": "08035", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Investigational Site Number 724001", "city": "Barcelona", "zip": "08036", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Investigational Site Number 724010", "city": "Palma De Mallorca", "zip": "07120", "country": "Spain", "geoPoint": {"lat": 39.56939, "lon": 2.65024}}, {"facility": "Investigational Site Number 724005", "city": "Pozuelo De Alarc\u00f3n", "zip": "28223", "country": "Spain", "geoPoint": {"lat": 40.43293, "lon": -3.81338}}, {"facility": "Investigational Site Number 724004", "city": "Sant Boi De Llobregat", "zip": "08830", "country": "Spain", "geoPoint": {"lat": 41.34357, "lon": 2.03659}}, {"facility": "Investigational Site Number 724006", "city": "Santiago De Compostela", "zip": "15706", "country": "Spain", "geoPoint": {"lat": 42.88052, "lon": -8.54569}}, {"facility": "Investigational Site Number 724008", "city": "Sevilla", "zip": "41071", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"facility": "Investigational Site Number 724007", "city": "Valencia", "zip": "46017", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Investigational Site Number 158004", "city": "Kaohsiung", "zip": "807", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"facility": "Investigational Site Number 158002", "city": "Kaohsiung", "zip": "82445", "country": "Taiwan", "geoPoint": {"lat": 22.61626, "lon": 120.31333}}, {"facility": "Investigational Site Number 158008", "city": "New Taipei City", "zip": "23561", "country": "Taiwan", "geoPoint": {"lat": 25.01111, "lon": 121.44583}}, {"facility": "Investigational Site Number 158005", "city": "Taichung", "zip": "40201", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Investigational Site Number 158007", "city": "Taichung", "zip": "40447", "country": "Taiwan", "geoPoint": {"lat": 24.1469, "lon": 120.6839}}, {"facility": "Investigational Site Number 158001", "city": "Taipei", "zip": "10043", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Investigational Site Number 158009", "city": "Taipei", "zip": "11031", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Investigational Site Number 158006", "city": "Taoyuan", "zip": "333", "country": "Taiwan", "geoPoint": {"lat": 24.95233, "lon": 121.20193}}, {"facility": "Investigational Site Number 792004", "city": "Ankara", "zip": "06100", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Investigational Site Number 792008", "city": "Ankara", "zip": "06100", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Investigational Site Number 792003", "city": "Bursa", "zip": "16059", "country": "Turkey", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}, {"facility": "Investigational Site Number 792001", "city": "Istanbul", "zip": "34098", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Investigational Site Number 792007", "city": "Istanbul", "zip": "34668", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Investigational Site Number 792005", "city": "Izmir", "zip": "35040", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}, {"facility": "Investigational Site Number 792010", "city": "Izmir", "zip": "35110", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}, {"facility": "Investigational Site Number 792009", "city": "Kirikkale", "zip": "71450", "country": "Turkey", "geoPoint": {"lat": 39.84528, "lon": 33.50639}}, {"facility": "Investigational Site Number 792011", "city": "Kocaeli", "zip": "41100", "country": "Turkey", "geoPoint": {"lat": 39.62497, "lon": 27.51145}}, {"facility": "Investigational Site Number 792002", "city": "Mersin", "zip": "33070", "country": "Turkey", "geoPoint": {"lat": 36.79526, "lon": 34.61792}}, {"facility": "Investigational Site Number 792006", "city": "Rize", "zip": "53100", "country": "Turkey", "geoPoint": {"lat": 41.02083, "lon": 40.52194}}, {"facility": "Investigational Site Number 804007", "city": "Chernivtsi", "zip": "58001", "country": "Ukraine", "geoPoint": {"lat": 48.29149, "lon": 25.94034}}, {"facility": "Investigational Site Number 804023", "city": "Dnipro", "zip": "49101", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Investigational Site Number 804004", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Investigational Site Number 804009", "city": "Ivano-Frankivsk", "zip": "76018", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Investigational Site Number 804005", "city": "Kharkiv", "zip": "61058", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Investigational Site Number 804021", "city": "Kharkiv", "zip": "61093", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Investigational Site Number 804001", "city": "Kharkiv", "zip": "61124", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Investigational Site Number 804003", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804008", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804011", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804013", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804017", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804016", "city": "Kyiv", "zip": "04050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Investigational Site Number 804006", "city": "Odessa", "zip": "65025", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Investigational Site Number 804002", "city": "Poltava", "zip": "36038", "country": "Ukraine", "geoPoint": {"lat": 49.59373, "lon": 34.54073}}, {"facility": "Investigational Site Number 804014", "city": "Ternopil", "zip": "46000", "country": "Ukraine", "geoPoint": {"lat": 49.55589, "lon": 25.60556}}, {"facility": "Investigational Site Number 804012", "city": "Vinnytsya", "zip": "21001", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "Investigational Site Number 804022", "city": "Zaporizhia", "zip": "69076", "country": "Ukraine", "geoPoint": {"lat": 47.82289, "lon": 35.19031}}, {"facility": "Investigational Site Number 826001", "city": "Bradford", "zip": "BD9 6RJ", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "Investigational Site Number 826002", "city": "London", "zip": "EC1M 6BQ", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Investigational Site Number 826005", "city": "Newcastle Upon Tyne", "zip": "NE7 7DN", "country": "United Kingdom", "geoPoint": {"lat": 54.97328, "lon": -1.61396}}, {"facility": "Investigational Site Number 826007", "city": "Portsmouth", "zip": "PO6 3LY", "country": "United Kingdom", "geoPoint": {"lat": 50.79899, "lon": -1.09125}}, {"facility": "Investigational Site Number 826006", "city": "South Shields", "zip": "NE34 0PL", "country": "United Kingdom", "geoPoint": {"lat": 54.99859, "lon": -1.4323}}, {"facility": "Investigational Site Number 826003", "city": "Sutton-In-Ashfield", "zip": "NG17 4JL", "country": "United Kingdom", "geoPoint": {"lat": 53.12542, "lon": -1.26135}}]}, "referencesModule": {"references": [{"pmid": "29782217", "type": "RESULT", "citation": "Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21."}, {"pmid": "36087550", "type": "DERIVED", "citation": "Bourdin A, Virchow JC, Papi A, Lugogo NL, Bardin P, Antila M, Halpin DMG, Daizadeh N, Djandji M, Ortiz B, Jacob-Nara JA, Gall R, Deniz Y, Rowe PJ. Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline. Respir Med. 2022 Oct;202:106938. doi: 10.1016/j.rmed.2022.106938. Epub 2022 Aug 11."}, {"pmid": "35899469", "type": "DERIVED", "citation": "Papi A, Corren J, Castro M, Domingo C, Rogers L, Chapman KR, Jackson DJ, Daizadeh N, Pandit-Abid N, Gall R, Jacob-Nara JA, Rowe PJ, Deniz Y, Ortiz B. Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma. Allergy. 2023 Jan;78(1):233-243. doi: 10.1111/all.15456. Epub 2022 Aug 9."}, {"pmid": "35636689", "type": "DERIVED", "citation": "Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28."}, {"pmid": "35487538", "type": "DERIVED", "citation": "Rabe KF, Pavord ID, Castro M, Wechsler ME, Daizadeh N, Kapoor U, Ortiz B, Radwan A, Johnson RR, Rowe PJ, Deniz Y, Jacob-Nara JA. Dupilumab efficacy and safety in patients with asthma and blood eosinophils >/=500 cells.microL-1. Eur Respir J. 2022 Jun 23;59(6):2102577. doi: 10.1183/13993003.02577-2021. Print 2022 Jun."}, {"pmid": "35255536", "type": "DERIVED", "citation": "Rhee CK, Park JW, Park HW, Cho YS. Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis. Allergy Asthma Immunol Res. 2022 Mar;14(2):182-195. doi: 10.4168/aair.2022.14.2.182."}, {"pmid": "34954123", "type": "DERIVED", "citation": "Geng B, Bachert C, Busse WW, Gevaert P, Lee SE, Niederman MS, Chen Z, Lu X, Khokhar FA, Kapoor U, Pandit-Abid N, Jacob-Nara JA, Rowe PJ, Deniz Y, Ortiz B. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies. J Allergy Clin Immunol Pract. 2022 Mar;10(3):732-741. doi: 10.1016/j.jaip.2021.12.006. Epub 2021 Dec 22."}, {"pmid": "34752208", "type": "DERIVED", "citation": "Tohda Y, Matsumoto H, Miyata M, Taguchi Y, Ueyama M, Joulain F, Arakawa I. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan. J Asthma. 2022 Nov;59(11):2162-2173. doi: 10.1080/02770903.2021.1996596. Epub 2021 Dec 8."}, {"pmid": "34326187", "type": "DERIVED", "citation": "Busse WW, Paggiaro P, Munoz X, Casale TB, Castro M, Canonica GW, Douglass JA, Tohda Y, Daizadeh N, Ortiz B, Pandit-Abid N. Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. Eur Respir J. 2021 Oct 7;58(4):2004605. doi: 10.1183/13993003.04605-2020. Print 2021 Oct."}, {"pmid": "34266940", "type": "DERIVED", "citation": "Corren J, Katelaris CH, Castro M, Maspero JF, Ford LB, Halpin DMG, Rice MS, Radwan A, Deniz Y, Rowe PJ, Teper A, Djandji M. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma. Eur Respir J. 2021 Oct 28;58(4):2004498. doi: 10.1183/13993003.04498-2020. Print 2021 Oct."}, {"pmid": "34181876", "type": "DERIVED", "citation": "Busse WW, Wenzel SE, Casale TB, FitzGerald JM, Rice MS, Daizadeh N, Deniz Y, Patel N, Harel S, Rowe PJ, Graham NMH, O'Riordan T, Pavord ID. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021 Oct;9(10):1165-1173. doi: 10.1016/S2213-2600(21)00124-7. Epub 2021 Jun 25."}, {"pmid": "34037993", "type": "DERIVED", "citation": "Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, Amin N, Ardeleanu M, Radin A, Shumel B, Ruddy M, Patel N, Pirozzi G, Mannent L, Graham NMH. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021 Jul;51(7):915-931. doi: 10.1111/cea.13954. Epub 2021 Jun 26."}, {"pmid": "33905544", "type": "DERIVED", "citation": "Maspero JF, FitzGerald JM, Pavord ID, Rice MS, Maroni J, Rowe PJ, Pirozzi G, Amin N, Ruddy M, Graham NMH, Teper A, Hardin M. Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST. Allergy. 2021 Aug;76(8):2621-2624. doi: 10.1111/all.14872. Epub 2021 May 10. No abstract available."}, {"pmid": "33481203", "type": "DERIVED", "citation": "Bansal A, Simpson EL, Paller AS, Siegfried EC, Blauvelt A, de Bruin-Weller M, Corren J, Sher L, Guttman-Yassky E, Chen Z, Daizadeh N, Kamal MA, Shumel B, Mina-Osorio P, Mannent L, Patel N, Graham NMH, Khokhar FA, Ardeleanu M. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. Am J Clin Dermatol. 2021 Jan;22(1):101-115. doi: 10.1007/s40257-020-00577-1."}, {"pmid": "33010038", "type": "DERIVED", "citation": "Bourdin A, Papi AA, Corren J, Virchow JC, Rice MS, Deniz Y, Djandji M, Rowe P, Pavord ID. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Allergy. 2021 Jan;76(1):269-280. doi: 10.1111/all.14611. Epub 2020 Oct 21."}, {"pmid": "32444306", "type": "DERIVED", "citation": "Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Arima K, Miyata M, Takahashi Y, Rice MS, Deniz Y, Rowe P, Patel N, Graham NMH, Teper A. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study. Allergol Int. 2020 Oct;69(4):578-587. doi: 10.1016/j.alit.2020.04.002. Epub 2020 May 20."}, {"pmid": "31521831", "type": "DERIVED", "citation": "Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan AH, Kamat S, Maroni J, Rowe P, Lu Y, Amin N, Pirozzi G, Ruddy M, Graham NMH, Teper A. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526. doi: 10.1016/j.jaip.2019.08.050. Epub 2019 Sep 12."}, {"pmid": "31351189", "type": "DERIVED", "citation": "Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, Peters AT, Pavord ID, Ford LB, Sher L, Rabe KF, Rice MS, Rowe P, Lu Y, Harel S, Jagerschmidt A, Khan AH, Kamat S, Pirozzi G, Amin N, Ruddy M, Graham NMH, Mannent LP, Teper A. Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. J Allergy Clin Immunol Pract. 2020 Feb;8(2):527-539.e9. doi: 10.1016/j.jaip.2019.07.016. Epub 2019 Jul 24."}, {"pmid": "30138668", "type": "DERIVED", "citation": "Corren J, Castro M, Chanez P, Fabbri L, Joish VN, Amin N, Graham NMH, Mastey V, Abbe A, Taniou C, Mahajan P, Teper A, Pirozzi G, Eckert L. Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma. Ann Allergy Asthma Immunol. 2019 Jan;122(1):41-49.e2. doi: 10.1016/j.anai.2018.08.005. Epub 2018 Aug 21."}, {"pmid": "29725983", "type": "DERIVED", "citation": "Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A. Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Adv Ther. 2018 May;35(5):737-748. doi: 10.1007/s12325-018-0702-4. Epub 2018 May 3."}, {"pmid": "29355679", "type": "DERIVED", "citation": "Weinstein SF, Katial R, Jayawardena S, Pirozzi G, Staudinger H, Eckert L, Joish VN, Amin N, Maroni J, Rowe P, Graham NMH, Teper A. Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma. J Allergy Clin Immunol. 2018 Jul;142(1):171-177.e1. doi: 10.1016/j.jaci.2017.11.051. Epub 2018 Jan 31."}], "seeAlsoLinks": [{"label": "Related Info", "url": "https://www.ncbi.nlm.nih.gov/pubmed/?term=29782217&report=abstract"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Randomization was stratified by age (\\<18 years, \\>=18 years), blood eosinophil count(\\<0.3 Giga/L, \\>=0.3 Giga/L), ICS dose level (medium, high), and country. Assignment to arms was done centrally using Interactive Voice/Web Response System in 2:2:1:1 ratio to Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for 200 mg)q2w, Placebo (for 300 mg)q2w", "recruitmentDetails": "4148 participants were screened from Apr 2015-Sep 2016. 1902 were randomized at 321 centers/22 countries. 2246 were screen failures. 1897 participants were treated; some received a different treatment than that assigned at randomization and for adverse event (AE) analysis were allocated to treatment actually received (see footnotes in below table)", "groups": [{"id": "FG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable inhaled corticosteroid (ICS) and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "FG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "FG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "FG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "Randomized", "achievements": [{"groupId": "FG000", "numSubjects": "317"}, {"groupId": "FG001", "numSubjects": "631"}, {"groupId": "FG002", "numSubjects": "321"}, {"groupId": "FG003", "numSubjects": "633"}]}, {"type": "Treated", "comment": "Randomized", "achievements": [{"groupId": "FG000", "comment": "2 got other treatment (1 each dupilumab 200+300) than assigned + were allocated to those in AE table", "numSubjects": "315"}, {"groupId": "FG001", "numSubjects": "629"}, {"groupId": "FG002", "numSubjects": "321"}, {"groupId": "FG003", "comment": "1 got other treatment (dupilumab 200) than assigned + was allocated to that in AE table", "numSubjects": "632"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "295"}, {"groupId": "FG001", "numSubjects": "586"}, {"groupId": "FG002", "numSubjects": "301"}, {"groupId": "FG003", "numSubjects": "582"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "45"}, {"groupId": "FG002", "numSubjects": "20"}, {"groupId": "FG003", "numSubjects": "51"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "12"}]}, {"type": "Poor compliance to protocol", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Other than specified above", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "37"}, {"groupId": "FG002", "numSubjects": "17"}, {"groupId": "FG003", "numSubjects": "37"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Analysis was performed on all randomized participants.", "groups": [{"id": "BG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "BG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "BG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "BG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "48.2", "spread": "15.6"}, {"groupId": "BG001", "value": "47.9", "spread": "15.3"}, {"groupId": "BG002", "value": "48.2", "spread": "14.7"}, {"groupId": "BG003", "value": "47.7", "spread": "15.6"}, {"groupId": "BG004", "value": "47.9", "spread": "15.3"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Adolescents (12-17 years)", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "34"}, {"groupId": "BG004", "value": "107"}]}]}, {"title": "Adults (18-64 years)", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "253"}, {"groupId": "BG001", "value": "512"}, {"groupId": "BG002", "value": "263"}, {"groupId": "BG003", "value": "516"}, {"groupId": "BG004", "value": "1544"}]}]}, {"title": "From 65-84 years", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "85"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "83"}, {"groupId": "BG004", "value": "251"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "198"}, {"groupId": "BG001", "value": "387"}, {"groupId": "BG002", "value": "218"}, {"groupId": "BG003", "value": "394"}, {"groupId": "BG004", "value": "1197"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "119"}, {"groupId": "BG001", "value": "244"}, {"groupId": "BG002", "value": "103"}, {"groupId": "BG003", "value": "239"}, {"groupId": "BG004", "value": "705"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "81"}, {"groupId": "BG001", "value": "171"}, {"groupId": "BG002", "value": "79"}, {"groupId": "BG003", "value": "159"}, {"groupId": "BG004", "value": "490"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "236"}, {"groupId": "BG001", "value": "460"}, {"groupId": "BG002", "value": "242"}, {"groupId": "BG003", "value": "474"}, {"groupId": "BG004", "value": "1412"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Caucasian/White", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "265"}, {"groupId": "BG001", "value": "510"}, {"groupId": "BG002", "value": "273"}, {"groupId": "BG003", "value": "529"}, {"groupId": "BG004", "value": "1577"}]}]}, {"title": "Black/of African descent", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "21"}, {"groupId": "BG004", "value": "80"}]}]}, {"title": "Asian/Oriental", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "33"}, {"groupId": "BG003", "value": "79"}, {"groupId": "BG004", "value": "223"}]}]}, {"title": "American Indian or Alaska Native", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "1"}]}]}, {"title": "Other", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "20"}]}]}]}, {"title": "Blood Eosinophil Group", "populationDescription": "Number analyzed = Number of participants with eosinophil data.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "<0.15 Giga/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "630"}, {"groupId": "BG002", "value": "320"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1900"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "193"}, {"groupId": "BG002", "value": "83"}, {"groupId": "BG003", "value": "181"}, {"groupId": "BG004", "value": "542"}]}]}, {"title": ">=0.15 - <0.3 Giga/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "630"}, {"groupId": "BG002", "value": "320"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1900"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "173"}, {"groupId": "BG002", "value": "95"}, {"groupId": "BG003", "value": "175"}, {"groupId": "BG004", "value": "527"}]}]}, {"title": ">=0.3 Giga/L", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "630"}, {"groupId": "BG002", "value": "320"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1900"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "148"}, {"groupId": "BG001", "value": "264"}, {"groupId": "BG002", "value": "142"}, {"groupId": "BG003", "value": "277"}, {"groupId": "BG004", "value": "831"}]}]}]}, {"title": "ICS Dose Level", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "High", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "172"}, {"groupId": "BG001", "value": "317"}, {"groupId": "BG002", "value": "167"}, {"groupId": "BG003", "value": "323"}, {"groupId": "BG004", "value": "979"}]}]}, {"title": "Medium", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "144"}, {"groupId": "BG001", "value": "310"}, {"groupId": "BG002", "value": "151"}, {"groupId": "BG003", "value": "303"}, {"groupId": "BG004", "value": "908"}]}]}, {"title": "Low", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "317"}, {"groupId": "BG001", "value": "631"}, {"groupId": "BG002", "value": "321"}, {"groupId": "BG003", "value": "633"}, {"groupId": "BG004", "value": "1902"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "15"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "populationDescription": "Analysis was performed on ITT population that included all randomized population analyzed according to the treatment group allocated by randomization.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbation per participant-year", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.871", "lowerLimit": "0.724", "upperLimit": "1.048"}, {"groupId": "OG001", "value": "0.456", "lowerLimit": "0.389", "upperLimit": "0.534"}, {"groupId": "OG002", "value": "0.970", "lowerLimit": "0.810", "upperLimit": "1.160"}, {"groupId": "OG003", "value": "0.524", "lowerLimit": "0.450", "upperLimit": "0.611"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "Analysis was performed using negative binomial model with total number of events onset from randomization up to Week 52 or last contact date (whichever comes earlier) as response variable; with 4 treatment groups, age, region, baseline eosinophil strata, baseline ICS dose level, number of severe exacerbation events within 1 year prior to study as covariates; and log transformed standardized observation duration as an offset variable. Here, it is test no. 1 of testing order.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Hierarchical testing procedure was used to control type I error rate at 0.05 level. The procedure included the 2 primary outcome measures and the first 13 secondary outcome measures reported and considered 2 pair-wise comparisons: Dupilumab 200 mg q2w vs Placebo (for Dupilumab 200 mg) q2w and Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w. Testing order is specified in analysis description.", "pValue": "<0.0001", "pValueComment": "Hierarchical testing sequence performed continued only when previous outcome measures was statistically significant at 0.05. Threshold for significance at 0.05 level.", "statisticalMethod": "Negative binomial regression model", "paramType": "Relative risk", "paramValue": "0.54", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.43", "ciUpperLimit": "0.68", "estimateComment": "Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis was performed using negative binomial model with total number of events onset from randomization up to Week 52 or last contact date (whichever comes earlier) as response variable; with 4 treatment groups, age, region, baseline eosinophil strata, baseline ICS dose level, number of severe exacerbation events within 1 year prior to study as covariates; and log transformed standardized observation duration as an offset variable. Here, it is test no. 3 of testing order.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing according to the hierarchical testing procedure (performed only if previous outcome measures were statistically significant).", "pValue": "<0.0001", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "Negative binomial regression model", "paramType": "Relative risk", "paramValue": "0.523", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.413", "ciUpperLimit": "0.662", "estimateComment": "Dupilumab 200 mg q2w vs Placebo (for Dupilumab 200 mg) q2w"}]}, {"type": "PRIMARY", "title": "Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.76", "spread": "0.61"}, {"groupId": "OG001", "value": "1.78", "spread": "0.62"}, {"groupId": "OG002", "value": "1.75", "spread": "0.57"}, {"groupId": "OG003", "value": "1.78", "spread": "0.60"}]}]}, {"title": "Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "611"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "610"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.92", "spread": "0.70"}, {"groupId": "OG001", "value": "2.07", "spread": "0.76"}, {"groupId": "OG002", "value": "1.93", "spread": "0.68"}, {"groupId": "OG003", "value": "2.09", "spread": "0.70"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "611"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "610"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.15", "spread": "0.36"}, {"groupId": "OG001", "value": "0.28", "spread": "0.45"}, {"groupId": "OG002", "value": "0.18", "spread": "0.39"}, {"groupId": "OG003", "value": "0.31", "spread": "0.43"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "Analysis was performed using mixed-effect model with repeated measures (MMRM) model with change from baseline in FEV1 values up to Week 12 as response variable; and treatment, age, sex, baseline height, region, baseline eosinophil strata, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEV1 value and baseline-by-visit interaction as covariates. Here, it is test no. 2 of testing order.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing according to the hierarchical testing procedure (performed only if previous outcome measures were statistically significant).", "pValue": "<0.0001", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "Mixed Models Analysis", "paramType": "Least Square (LS) Mean Difference", "paramValue": "0.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.08", "ciUpperLimit": "0.18", "estimateComment": "Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis was performed using MMRM model with change from baseline in FEV1 values up to Week 12 as response variable; and treatment, age, sex, baseline height, region, baseline eosinophil strata, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEV1 value and baseline-by-visit interaction as covariates. Here, it is test no. 4 of testing order.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing according to the hierarchical testing procedure (performed only if previous outcome measures were statistically significant).", "pValue": "<0.0001", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "0.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.08", "ciUpperLimit": "0.19", "estimateComment": "Dupilumab 200 mg q2w vs Placebo (for Dupilumab 200 mg) q2w"}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed on ITT population. 'Overall number of participants analyzed'=participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "611"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "610"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.16", "spread": "23.88"}, {"groupId": "OG001", "value": "18.74", "spread": "30.86"}, {"groupId": "OG002", "value": "11.87", "spread": "26.40"}, {"groupId": "OG003", "value": "20.89", "spread": "34.14"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "Analysis performed using MMRM model(n=954 for 300 vs placebo)with percent change from baseline in FEV1 values up to Week 12 as response variable; \\& treatment, age, sex, baseline height, region, baseline eosinophil strata, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEV1 value \\& baseline-by-visit interaction as covariates. Hierarchical testing procedure used to control type I error \\& handle multiple secondary endpoint analyses. Here, it is test no. 5 of testing order.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing according to the hierarchical testing procedure (performed only if previous outcome measures were statistically significant).", "pValue": "<0.0001", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "9.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "5.74", "ciUpperLimit": "13.07", "estimateComment": "Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w"}]}, {"type": "SECONDARY", "title": "Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "populationDescription": "Analysis was performed ITT population with baseline eosinophil \\>=0.15 Giga/L.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbation per participant-year", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "232"}, {"groupId": "OG001", "value": "437"}, {"groupId": "OG002", "value": "237"}, {"groupId": "OG003", "value": "452"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.007", "lowerLimit": "0.814", "upperLimit": "1.245"}, {"groupId": "OG001", "value": "0.445", "lowerLimit": "0.368", "upperLimit": "0.538"}, {"groupId": "OG002", "value": "1.081", "lowerLimit": "0.879", "upperLimit": "1.329"}, {"groupId": "OG003", "value": "0.434", "lowerLimit": "0.359", "upperLimit": "0.525"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "Analysis was performed using negative binomial model with total number of events onset from randomization up to Week 52 or last contact date (whichever comes earlier) as response variable; with 4 treatment groups, age, region, baseline eosinophil strata, baseline ICS dose level, number of severe exacerbation events within 1 year prior to study as covariates; and log transformed standardized observation duration as an offset variable. Here, it is test no. 6 of testing order.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing according to the hierarchical testing procedure (performed only if previous outcome measures were statistically significant).", "pValue": "<0.0001", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "Negative binomial regression model", "paramType": "Relative risk", "paramValue": "0.402", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.307", "ciUpperLimit": "0.526", "estimateComment": "Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w"}]}, {"type": "SECONDARY", "title": "Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed ITT population with baseline eosinophil \\>=0.15 Giga/L. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "232"}, {"groupId": "OG001", "value": "437"}, {"groupId": "OG002", "value": "237"}, {"groupId": "OG003", "value": "452"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "232"}, {"groupId": "OG001", "value": "437"}, {"groupId": "OG002", "value": "237"}, {"groupId": "OG003", "value": "452"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.77", "spread": "0.63"}, {"groupId": "OG001", "value": "1.81", "spread": "0.63"}, {"groupId": "OG002", "value": "1.75", "spread": "0.55"}, {"groupId": "OG003", "value": "1.79", "spread": "0.59"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "425"}, {"groupId": "OG002", "value": "229"}, {"groupId": "OG003", "value": "434"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "spread": "0.36"}, {"groupId": "OG001", "value": "0.34", "spread": "0.46"}, {"groupId": "OG002", "value": "0.21", "spread": "0.38"}, {"groupId": "OG003", "value": "0.35", "spread": "0.45"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "Analysis was performed using MMRM model with change from baseline in FEV1 values up to Week 12 as response variable; and treatment, age, sex, baseline height, region, baseline eosinophil strata, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEV1 value and baseline-by-visit interaction as covariates. Here, it is test no. 7 of testing order.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing according to the hierarchical testing procedure (performed only if previous outcome measures were statistically significant).", "pValue": "<0.0001", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.09", "ciUpperLimit": "0.21", "estimateComment": "Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w"}]}, {"type": "SECONDARY", "title": "Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "populationDescription": "Analysis was performed on ITT population with baseline eosinophil \\>=0.3 Giga/L.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbation per participant-year", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "264"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "277"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.081", "lowerLimit": "0.846", "upperLimit": "1.382"}, {"groupId": "OG001", "value": "0.370", "lowerLimit": "0.289", "upperLimit": "0.475"}, {"groupId": "OG002", "value": "1.236", "lowerLimit": "0.972", "upperLimit": "1.571"}, {"groupId": "OG003", "value": "0.403", "lowerLimit": "0.317", "upperLimit": "0.512"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "Analysis was performed using negative binomial model with total number of events onset from randomization up to Week 52 or last contact date (whichever comes earlier) as response variable; with 4 treatment groups, age, region, baseline eosinophil strata, baseline ICS dose level, number of severe exacerbation events within 1 year prior to study as covariates; and log transformed standardized observation duration as an offset variable. Here, it is test no. 8 of testing order.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing according to the hierarchical testing procedure (performed only if previous outcome measures were statistically significant).", "pValue": "<0.0001", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "Negative binomial regression model", "paramType": "Relative risk", "paramValue": "0.326", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.234", "ciUpperLimit": "0.454", "estimateComment": "Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w"}]}, {"type": "SECONDARY", "title": "Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed ITT population with baseline eosinophil \\>=0.3 Giga/L. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "264"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "277"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "264"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "277"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.78", "spread": "0.66"}, {"groupId": "OG001", "value": "1.81", "spread": "0.64"}, {"groupId": "OG002", "value": "1.73", "spread": "0.54"}, {"groupId": "OG003", "value": "1.75", "spread": "0.59"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "256"}, {"groupId": "OG002", "value": "139"}, {"groupId": "OG003", "value": "266"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.19", "spread": "0.39"}, {"groupId": "OG001", "value": "0.39", "spread": "0.45"}, {"groupId": "OG002", "value": "0.20", "spread": "0.40"}, {"groupId": "OG003", "value": "0.43", "spread": "0.43"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "Analysis was performed using MMRM model with change from baseline in FEV1 values up to Week 12 as response variable; and treatment, age, sex, baseline height, region, baseline eosinophil strata, baseline ICS dose level, visit, treatment by-visit interaction, baseline FEV1 value and baseline-by-visit interaction as covariates. Here, it is test no. 9 of testing order.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing according to the hierarchical testing procedure (performed only if previous outcome measures were statistically significant).", "pValue": "<0.0001", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "Mixed Models Analysis", "paramType": "LS Mean Difference", "paramValue": "0.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.16", "ciUpperLimit": "0.32", "estimateComment": "Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w"}]}, {"type": "SECONDARY", "title": "Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "populationDescription": "Analysis was performed on ITT population with baseline eosinophil \\<0.3 Giga/L.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbation per participant-year", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "169"}, {"groupId": "OG001", "value": "366"}, {"groupId": "OG002", "value": "178"}, {"groupId": "OG003", "value": "356"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.675", "lowerLimit": "0.515", "upperLimit": "0.884"}, {"groupId": "OG001", "value": "0.512", "lowerLimit": "0.418", "upperLimit": "0.628"}, {"groupId": "OG002", "value": "0.732", "lowerLimit": "0.562", "upperLimit": "0.954"}, {"groupId": "OG003", "value": "0.610", "lowerLimit": "0.502", "upperLimit": "0.742"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "Analysis was performed using negative binomial model with total number of events onset from randomization up to Week 52 or last contact date (whichever comes earlier) as response variable; with 4 treatment groups, age, region, baseline eosinophil strata, baseline ICS dose level, number of severe exacerbation events within 1 year prior to study as covariates; and log transformed standardized observation duration as an offset variable. Here, it is test no. 10 of testing order.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Testing according to the hierarchical testing procedure (performed only if previous outcome measures were statistically significant).", "pValue": "0.2599", "pValueComment": "Threshold for significance at 0.05 level.", "statisticalMethod": "Negative binomial regression model", "paramType": "Relative risk", "paramValue": "0.834", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.608", "ciUpperLimit": "1.144", "estimateComment": "Dupilumab 300 mg q2w vs Placebo (for Dupilumab 300 mg) q2w"}]}, {"type": "SECONDARY", "title": "Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.", "populationDescription": "Analysis was performed on ITT population with high dose ICS at baseline.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbation per participant-year", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "172"}, {"groupId": "OG001", "value": "317"}, {"groupId": "OG002", "value": "167"}, {"groupId": "OG003", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.040", "lowerLimit": "0.824", "upperLimit": "1.314"}, {"groupId": "OG001", "value": "0.560", "lowerLimit": "0.455", "upperLimit": "0.690"}, {"groupId": "OG002", "value": "1.038", "lowerLimit": "0.818", "upperLimit": "1.317"}, {"groupId": "OG003", "value": "0.639", "lowerLimit": "0.523", "upperLimit": "0.780"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed on ITT population with high dose ICS at baseline. 'Overall number of participants analysed'=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "167"}, {"groupId": "OG001", "value": "310"}, {"groupId": "OG002", "value": "162"}, {"groupId": "OG003", "value": "309"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.14", "spread": "0.34"}, {"groupId": "OG001", "value": "0.27", "spread": "0.42"}, {"groupId": "OG002", "value": "0.20", "spread": "0.40"}, {"groupId": "OG003", "value": "0.32", "spread": "0.43"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ [S]) Self-Administered Global Score at Week 24: ITT Population", "description": "The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "299"}, {"groupId": "OG001", "value": "591"}, {"groupId": "OG002", "value": "314"}, {"groupId": "OG003", "value": "603"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.26", "spread": "1.02"}, {"groupId": "OG001", "value": "4.31", "spread": "1.08"}, {"groupId": "OG002", "value": "4.30", "spread": "1.03"}, {"groupId": "OG003", "value": "4.28", "spread": "1.05"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "298"}, {"groupId": "OG001", "value": "592"}, {"groupId": "OG002", "value": "302"}, {"groupId": "OG003", "value": "596"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.23", "spread": "1.07"}, {"groupId": "OG001", "value": "5.46", "spread": "1.12"}, {"groupId": "OG002", "value": "5.30", "spread": "1.15"}, {"groupId": "OG003", "value": "5.47", "spread": "1.09"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "281"}, {"groupId": "OG001", "value": "560"}, {"groupId": "OG002", "value": "295"}, {"groupId": "OG003", "value": "569"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.95", "spread": "1.03"}, {"groupId": "OG001", "value": "1.13", "spread": "1.14"}, {"groupId": "OG002", "value": "1.02", "spread": "1.10"}, {"groupId": "OG003", "value": "1.17", "spread": "1.11"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in AQLQ (S) Self- Administered Global Score at Week 24: ITT Population With Baseline Eosinophil >=0.3 Giga/L", "description": "The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.", "populationDescription": "Analysis was performed on ITT population with baseline eosinophil \\>=0.3 Giga/L. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "264"}, {"groupId": "OG002", "value": "142"}, {"groupId": "OG003", "value": "277"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "254"}, {"groupId": "OG002", "value": "138"}, {"groupId": "OG003", "value": "263"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.24", "spread": "0.98"}, {"groupId": "OG001", "value": "4.24", "spread": "1.11"}, {"groupId": "OG002", "value": "4.21", "spread": "0.97"}, {"groupId": "OG003", "value": "4.36", "spread": "1.05"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "241"}, {"groupId": "OG002", "value": "130"}, {"groupId": "OG003", "value": "244"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.97", "spread": "1.01"}, {"groupId": "OG001", "value": "1.39", "spread": "1.15"}, {"groupId": "OG002", "value": "1.02", "spread": "1.25"}, {"groupId": "OG003", "value": "1.30", "spread": "1.15"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 24: ITT Population", "description": "The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.71", "spread": "0.73"}, {"groupId": "OG001", "value": "2.76", "spread": "0.80"}, {"groupId": "OG002", "value": "2.77", "spread": "0.77"}, {"groupId": "OG003", "value": "2.77", "spread": "0.76"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "296"}, {"groupId": "OG001", "value": "590"}, {"groupId": "OG002", "value": "297"}, {"groupId": "OG003", "value": "585"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.67", "spread": "1.06"}, {"groupId": "OG001", "value": "1.33", "spread": "1.05"}, {"groupId": "OG002", "value": "1.58", "spread": "1.08"}, {"groupId": "OG003", "value": "1.37", "spread": "1.10"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "296"}, {"groupId": "OG001", "value": "590"}, {"groupId": "OG002", "value": "297"}, {"groupId": "OG003", "value": "585"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.06", "spread": "1.01"}, {"groupId": "OG001", "value": "-1.43", "spread": "1.05"}, {"groupId": "OG002", "value": "-1.19", "spread": "1.10"}, {"groupId": "OG003", "value": "-1.38", "spread": "1.10"}]}]}]}, {"type": "SECONDARY", "title": "Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population", "description": "A severe exacerbation was defined as a deterioration of asthma requiring: use of systemic corticosteroids for \\>=3 days; or hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of exacerbations (resulted hospitalization or emergency room visit) that occurred during the treatment period divided by the total number of participant-years treated.", "populationDescription": "Analysis was performed on ITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbation per participant-year", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.081", "lowerLimit": "0.049", "upperLimit": "0.135"}, {"groupId": "OG001", "value": "0.043", "lowerLimit": "0.027", "upperLimit": "0.068"}, {"groupId": "OG002", "value": "0.034", "lowerLimit": "0.017", "upperLimit": "0.066"}, {"groupId": "OG003", "value": "0.025", "lowerLimit": "0.014", "upperLimit": "0.043"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed ITT population with baseline eosinophil \\<0.3 Giga/L. 'Overall number of participants analysed'=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "163"}, {"groupId": "OG001", "value": "354"}, {"groupId": "OG002", "value": "173"}, {"groupId": "OG003", "value": "344"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "0.32"}, {"groupId": "OG001", "value": "0.21", "spread": "0.43"}, {"groupId": "OG002", "value": "0.17", "spread": "0.39"}, {"groupId": "OG003", "value": "0.21", "spread": "0.41"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed on ITT population with baseline eosinophil \\>=0.3 Giga/L. 'Overall number of participants analyzed'=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "144"}, {"groupId": "OG001", "value": "256"}, {"groupId": "OG002", "value": "139"}, {"groupId": "OG003", "value": "266"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13.40", "spread": "27.01"}, {"groupId": "OG001", "value": "26.41", "spread": "33.69"}, {"groupId": "OG002", "value": "13.05", "spread": "25.27"}, {"groupId": "OG003", "value": "30.58", "spread": "38.22"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed on ITT population with high dose ICS at baseline. 'Overall number of participants analysed'=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "167"}, {"groupId": "OG001", "value": "310"}, {"groupId": "OG002", "value": "162"}, {"groupId": "OG003", "value": "309"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.47", "spread": "20.94"}, {"groupId": "OG001", "value": "17.99", "spread": "28.43"}, {"groupId": "OG002", "value": "13.22", "spread": "26.52"}, {"groupId": "OG003", "value": "23.41", "spread": "37.26"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed on ITT population with baseline eosinophil \\>=0.15 Giga/L. 'Overall number of participants analyzed'=participants evaluable for this outcome measure at specified timepoint.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "425"}, {"groupId": "OG002", "value": "229"}, {"groupId": "OG003", "value": "434"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.43", "spread": "24.71"}, {"groupId": "OG001", "value": "22.04", "spread": "31.96"}, {"groupId": "OG002", "value": "13.49", "spread": "25.18"}, {"groupId": "OG003", "value": "24.04", "spread": "35.71"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter", "timeFrame": "Baseline, Weeks 2, 4, 8, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "315"}, {"groupId": "OG001", "value": "610"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "625"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "spread": "0.35"}, {"groupId": "OG001", "value": "0.22", "spread": "0.38"}, {"groupId": "OG002", "value": "0.10", "spread": "0.34"}, {"groupId": "OG003", "value": "0.25", "spread": "0.40"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "613"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "614"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.35"}, {"groupId": "OG001", "value": "0.24", "spread": "0.40"}, {"groupId": "OG002", "value": "0.13", "spread": "0.34"}, {"groupId": "OG003", "value": "0.27", "spread": "0.41"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "305"}, {"groupId": "OG001", "value": "604"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "609"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.15", "spread": "0.38"}, {"groupId": "OG001", "value": "0.28", "spread": "0.42"}, {"groupId": "OG002", "value": "0.19", "spread": "0.40"}, {"groupId": "OG003", "value": "0.29", "spread": "0.43"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "296"}, {"groupId": "OG003", "value": "596"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.40"}, {"groupId": "OG001", "value": "0.31", "spread": "0.45"}, {"groupId": "OG002", "value": "0.19", "spread": "0.44"}, {"groupId": "OG003", "value": "0.30", "spread": "0.44"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}, {"groupId": "OG001", "value": "590"}, {"groupId": "OG002", "value": "301"}, {"groupId": "OG003", "value": "584"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.14", "spread": "0.41"}, {"groupId": "OG001", "value": "0.31", "spread": "0.48"}, {"groupId": "OG002", "value": "0.21", "spread": "0.42"}, {"groupId": "OG003", "value": "0.32", "spread": "0.45"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "240"}, {"groupId": "OG001", "value": "477"}, {"groupId": "OG002", "value": "250"}, {"groupId": "OG003", "value": "488"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "0.38"}, {"groupId": "OG001", "value": "0.31", "spread": "0.50"}, {"groupId": "OG002", "value": "0.20", "spread": "0.42"}, {"groupId": "OG003", "value": "0.32", "spread": "0.44"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Baseline, Weeks 2, 4, 8, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "315"}, {"groupId": "OG001", "value": "610"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "625"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.78", "spread": "23.36"}, {"groupId": "OG001", "value": "14.32", "spread": "26.55"}, {"groupId": "OG002", "value": "6.60", "spread": "21.84"}, {"groupId": "OG003", "value": "17.38", "spread": "30.82"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "613"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "614"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.61", "spread": "25.54"}, {"groupId": "OG001", "value": "16.11", "spread": "28.12"}, {"groupId": "OG002", "value": "8.67", "spread": "23.55"}, {"groupId": "OG003", "value": "18.77", "spread": "32.73"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "305"}, {"groupId": "OG001", "value": "604"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "609"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.27", "spread": "25.60"}, {"groupId": "OG001", "value": "18.81", "spread": "29.80"}, {"groupId": "OG002", "value": "12.24", "spread": "25.78"}, {"groupId": "OG003", "value": "19.85", "spread": "33.63"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "296"}, {"groupId": "OG003", "value": "596"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.42", "spread": "26.76"}, {"groupId": "OG001", "value": "19.76", "spread": "30.64"}, {"groupId": "OG002", "value": "12.86", "spread": "28.14"}, {"groupId": "OG003", "value": "20.75", "spread": "35.35"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}, {"groupId": "OG001", "value": "590"}, {"groupId": "OG002", "value": "301"}, {"groupId": "OG003", "value": "584"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.57", "spread": "26.41"}, {"groupId": "OG001", "value": "19.92", "spread": "32.26"}, {"groupId": "OG002", "value": "13.45", "spread": "27.69"}, {"groupId": "OG003", "value": "22.08", "spread": "35.93"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "240"}, {"groupId": "OG001", "value": "477"}, {"groupId": "OG002", "value": "250"}, {"groupId": "OG003", "value": "488"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.37", "spread": "23.59"}, {"groupId": "OG001", "value": "19.96", "spread": "33.35"}, {"groupId": "OG002", "value": "12.89", "spread": "27.70"}, {"groupId": "OG003", "value": "21.57", "spread": "34.08"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent predicted of FEV1", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "315"}, {"groupId": "OG001", "value": "610"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "625"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.58", "spread": "11.36"}, {"groupId": "OG001", "value": "7.10", "spread": "12.28"}, {"groupId": "OG002", "value": "3.32", "spread": "10.98"}, {"groupId": "OG003", "value": "8.44", "spread": "13.20"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "613"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "614"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.55", "spread": "11.69"}, {"groupId": "OG001", "value": "7.92", "spread": "12.81"}, {"groupId": "OG002", "value": "4.13", "spread": "11.41"}, {"groupId": "OG003", "value": "9.20", "spread": "14.10"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "305"}, {"groupId": "OG001", "value": "604"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "609"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.93", "spread": "12.30"}, {"groupId": "OG001", "value": "9.27", "spread": "13.13"}, {"groupId": "OG002", "value": "6.08", "spread": "12.55"}, {"groupId": "OG003", "value": "9.70", "spread": "14.15"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "611"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "610"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.02", "spread": "12.10"}, {"groupId": "OG001", "value": "9.22", "spread": "13.87"}, {"groupId": "OG002", "value": "5.90", "spread": "13.02"}, {"groupId": "OG003", "value": "10.28", "spread": "14.44"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "296"}, {"groupId": "OG003", "value": "596"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.38", "spread": "12.85"}, {"groupId": "OG001", "value": "9.98", "spread": "13.94"}, {"groupId": "OG002", "value": "6.41", "spread": "14.02"}, {"groupId": "OG003", "value": "10.14", "spread": "14.75"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}, {"groupId": "OG001", "value": "590"}, {"groupId": "OG002", "value": "301"}, {"groupId": "OG003", "value": "584"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.09", "spread": "12.99"}, {"groupId": "OG001", "value": "10.12", "spread": "14.61"}, {"groupId": "OG002", "value": "6.82", "spread": "13.54"}, {"groupId": "OG003", "value": "10.94", "spread": "15.06"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "240"}, {"groupId": "OG001", "value": "477"}, {"groupId": "OG002", "value": "250"}, {"groupId": "OG003", "value": "488"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.25", "spread": "12.06"}, {"groupId": "OG001", "value": "10.08", "spread": "14.79"}, {"groupId": "OG002", "value": "6.68", "spread": "13.56"}, {"groupId": "OG003", "value": "11.02", "spread": "14.59"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Morning (AM)/Evening (PM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters/min", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "AM: Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "314"}, {"groupId": "OG001", "value": "620"}, {"groupId": "OG002", "value": "320"}, {"groupId": "OG003", "value": "630"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.19", "spread": "31.30"}, {"groupId": "OG001", "value": "15.21", "spread": "39.45"}, {"groupId": "OG002", "value": "3.45", "spread": "28.95"}, {"groupId": "OG003", "value": "14.46", "spread": "36.29"}]}]}, {"title": "AM: Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "619"}, {"groupId": "OG002", "value": "319"}, {"groupId": "OG003", "value": "625"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.23", "spread": "42.42"}, {"groupId": "OG001", "value": "21.81", "spread": "53.85"}, {"groupId": "OG002", "value": "5.55", "spread": "43.69"}, {"groupId": "OG003", "value": "19.67", "spread": "46.47"}]}]}, {"title": "AM: Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "614"}, {"groupId": "OG002", "value": "318"}, {"groupId": "OG003", "value": "613"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.42", "spread": "49.30"}, {"groupId": "OG001", "value": "25.70", "spread": "58.52"}, {"groupId": "OG002", "value": "12.22", "spread": "50.50"}, {"groupId": "OG003", "value": "23.18", "spread": "52.65"}]}]}, {"title": "AM: Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "305"}, {"groupId": "OG001", "value": "608"}, {"groupId": "OG002", "value": "314"}, {"groupId": "OG003", "value": "608"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.85", "spread": "50.40"}, {"groupId": "OG001", "value": "27.81", "spread": "65.30"}, {"groupId": "OG002", "value": "14.23", "spread": "56.18"}, {"groupId": "OG003", "value": "25.88", "spread": "57.09"}]}]}, {"title": "AM: Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "299"}, {"groupId": "OG001", "value": "590"}, {"groupId": "OG002", "value": "305"}, {"groupId": "OG003", "value": "588"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.55", "spread": "53.27"}, {"groupId": "OG001", "value": "28.71", "spread": "69.64"}, {"groupId": "OG002", "value": "15.43", "spread": "60.83"}, {"groupId": "OG003", "value": "23.74", "spread": "63.71"}]}]}, {"title": "AM: Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}, {"groupId": "OG001", "value": "576"}, {"groupId": "OG002", "value": "297"}, {"groupId": "OG003", "value": "564"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.24", "spread": "61.68"}, {"groupId": "OG001", "value": "31.19", "spread": "71.59"}, {"groupId": "OG002", "value": "12.57", "spread": "61.88"}, {"groupId": "OG003", "value": "23.93", "spread": "65.04"}]}]}, {"title": "AM: Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "270"}, {"groupId": "OG001", "value": "544"}, {"groupId": "OG002", "value": "282"}, {"groupId": "OG003", "value": "529"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.85", "spread": "64.60"}, {"groupId": "OG001", "value": "29.86", "spread": "75.44"}, {"groupId": "OG002", "value": "10.99", "spread": "64.68"}, {"groupId": "OG003", "value": "26.67", "spread": "71.63"}]}]}, {"title": "PM: Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "617"}, {"groupId": "OG002", "value": "319"}, {"groupId": "OG003", "value": "629"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.33", "spread": "36.81"}, {"groupId": "OG001", "value": "13.80", "spread": "40.59"}, {"groupId": "OG002", "value": "3.87", "spread": "33.98"}, {"groupId": "OG003", "value": "11.35", "spread": "36.10"}]}]}, {"title": "PM: Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "312"}, {"groupId": "OG001", "value": "617"}, {"groupId": "OG002", "value": "319"}, {"groupId": "OG003", "value": "623"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.01", "spread": "45.09"}, {"groupId": "OG001", "value": "17.94", "spread": "55.30"}, {"groupId": "OG002", "value": "2.73", "spread": "46.83"}, {"groupId": "OG003", "value": "14.90", "spread": "47.42"}]}]}, {"title": "PM: Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "613"}, {"groupId": "OG002", "value": "315"}, {"groupId": "OG003", "value": "610"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.82", "spread": "50.10"}, {"groupId": "OG001", "value": "21.06", "spread": "61.80"}, {"groupId": "OG002", "value": "7.68", "spread": "56.73"}, {"groupId": "OG003", "value": "17.26", "spread": "53.37"}]}]}, {"title": "PM: Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "306"}, {"groupId": "OG001", "value": "606"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "605"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.24", "spread": "53.42"}, {"groupId": "OG001", "value": "19.75", "spread": "68.14"}, {"groupId": "OG002", "value": "8.52", "spread": "56.74"}, {"groupId": "OG003", "value": "18.70", "spread": "55.60"}]}]}, {"title": "PM: Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "299"}, {"groupId": "OG001", "value": "583"}, {"groupId": "OG002", "value": "300"}, {"groupId": "OG003", "value": "585"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.89", "spread": "55.07"}, {"groupId": "OG001", "value": "19.95", "spread": "71.50"}, {"groupId": "OG002", "value": "7.56", "spread": "63.25"}, {"groupId": "OG003", "value": "15.82", "spread": "61.91"}]}]}, {"title": "PM: Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "286"}, {"groupId": "OG001", "value": "570"}, {"groupId": "OG002", "value": "291"}, {"groupId": "OG003", "value": "557"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.75", "spread": "62.44"}, {"groupId": "OG001", "value": "21.79", "spread": "75.00"}, {"groupId": "OG002", "value": "2.64", "spread": "65.21"}, {"groupId": "OG003", "value": "14.35", "spread": "64.66"}]}]}, {"title": "PM: Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "526"}, {"groupId": "OG002", "value": "268"}, {"groupId": "OG003", "value": "523"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.43", "spread": "62.82"}, {"groupId": "OG001", "value": "18.77", "spread": "77.37"}, {"groupId": "OG002", "value": "2.83", "spread": "67.01"}, {"groupId": "OG003", "value": "15.58", "spread": "72.51"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "315"}, {"groupId": "OG001", "value": "610"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "625"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "spread": "0.42"}, {"groupId": "OG001", "value": "0.23", "spread": "0.44"}, {"groupId": "OG002", "value": "0.10", "spread": "0.37"}, {"groupId": "OG003", "value": "0.25", "spread": "0.46"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "613"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "614"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "0.39"}, {"groupId": "OG001", "value": "0.26", "spread": "0.45"}, {"groupId": "OG002", "value": "0.12", "spread": "0.38"}, {"groupId": "OG003", "value": "0.27", "spread": "0.47"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "305"}, {"groupId": "OG001", "value": "604"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "609"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.41"}, {"groupId": "OG001", "value": "0.28", "spread": "0.45"}, {"groupId": "OG002", "value": "0.18", "spread": "0.42"}, {"groupId": "OG003", "value": "0.29", "spread": "0.50"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "611"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "610"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.41"}, {"groupId": "OG001", "value": "0.29", "spread": "0.49"}, {"groupId": "OG002", "value": "0.18", "spread": "0.44"}, {"groupId": "OG003", "value": "0.29", "spread": "0.51"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "296"}, {"groupId": "OG003", "value": "596"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "spread": "0.45"}, {"groupId": "OG001", "value": "0.29", "spread": "0.48"}, {"groupId": "OG002", "value": "0.18", "spread": "0.46"}, {"groupId": "OG003", "value": "0.29", "spread": "0.51"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}, {"groupId": "OG001", "value": "590"}, {"groupId": "OG002", "value": "301"}, {"groupId": "OG003", "value": "584"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "spread": "0.45"}, {"groupId": "OG001", "value": "0.30", "spread": "0.52"}, {"groupId": "OG002", "value": "0.19", "spread": "0.47"}, {"groupId": "OG003", "value": "0.31", "spread": "0.52"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "240"}, {"groupId": "OG001", "value": "477"}, {"groupId": "OG002", "value": "250"}, {"groupId": "OG003", "value": "488"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "spread": "0.45"}, {"groupId": "OG001", "value": "0.29", "spread": "0.53"}, {"groupId": "OG002", "value": "0.18", "spread": "0.45"}, {"groupId": "OG003", "value": "0.31", "spread": "0.50"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "FEF is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEF25-75% is defined as the mean forced expiratory flow between the 25% and 75% of the FVC.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liters/sec", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "315"}, {"groupId": "OG001", "value": "610"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "625"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.09", "spread": "0.40"}, {"groupId": "OG001", "value": "0.22", "spread": "0.47"}, {"groupId": "OG002", "value": "0.11", "spread": "0.44"}, {"groupId": "OG003", "value": "0.27", "spread": "0.48"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "613"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "614"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "0.45"}, {"groupId": "OG001", "value": "0.24", "spread": "0.48"}, {"groupId": "OG002", "value": "0.15", "spread": "0.44"}, {"groupId": "OG003", "value": "0.29", "spread": "0.48"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "305"}, {"groupId": "OG001", "value": "604"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "609"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.18", "spread": "0.45"}, {"groupId": "OG001", "value": "0.29", "spread": "0.52"}, {"groupId": "OG002", "value": "0.20", "spread": "0.49"}, {"groupId": "OG003", "value": "0.32", "spread": "0.51"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "611"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "610"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.18", "spread": "0.46"}, {"groupId": "OG001", "value": "0.30", "spread": "0.53"}, {"groupId": "OG002", "value": "0.19", "spread": "0.50"}, {"groupId": "OG003", "value": "0.35", "spread": "0.53"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "300"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "296"}, {"groupId": "OG003", "value": "596"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "spread": "0.47"}, {"groupId": "OG001", "value": "0.34", "spread": "0.57"}, {"groupId": "OG002", "value": "0.22", "spread": "0.56"}, {"groupId": "OG003", "value": "0.35", "spread": "0.54"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}, {"groupId": "OG001", "value": "590"}, {"groupId": "OG002", "value": "301"}, {"groupId": "OG003", "value": "584"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.18", "spread": "0.49"}, {"groupId": "OG001", "value": "0.35", "spread": "0.59"}, {"groupId": "OG002", "value": "0.22", "spread": "0.49"}, {"groupId": "OG003", "value": "0.36", "spread": "0.56"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "240"}, {"groupId": "OG001", "value": "477"}, {"groupId": "OG002", "value": "250"}, {"groupId": "OG003", "value": "488"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": "0.50"}, {"groupId": "OG001", "value": "0.36", "spread": "0.63"}, {"groupId": "OG002", "value": "0.24", "spread": "0.55"}, {"groupId": "OG003", "value": "0.36", "spread": "0.55"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.", "populationDescription": "Analysis was performed ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "liter", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "310"}, {"groupId": "OG001", "value": "609"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "617"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.07", "spread": "0.31"}, {"groupId": "OG001", "value": "0.10", "spread": "0.37"}, {"groupId": "OG002", "value": "-0.04", "spread": "0.33"}, {"groupId": "OG003", "value": "0.09", "spread": "0.34"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "614"}, {"groupId": "OG002", "value": "311"}, {"groupId": "OG003", "value": "615"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "0.31"}, {"groupId": "OG001", "value": "0.10", "spread": "0.39"}, {"groupId": "OG002", "value": "-0.04", "spread": "0.36"}, {"groupId": "OG003", "value": "0.10", "spread": "0.36"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "305"}, {"groupId": "OG001", "value": "607"}, {"groupId": "OG002", "value": "305"}, {"groupId": "OG003", "value": "604"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "0.31"}, {"groupId": "OG001", "value": "0.12", "spread": "0.40"}, {"groupId": "OG002", "value": "0.03", "spread": "0.35"}, {"groupId": "OG003", "value": "0.11", "spread": "0.37"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "305"}, {"groupId": "OG001", "value": "610"}, {"groupId": "OG002", "value": "313"}, {"groupId": "OG003", "value": "612"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "0.33"}, {"groupId": "OG001", "value": "0.12", "spread": "0.40"}, {"groupId": "OG002", "value": "0.01", "spread": "0.35"}, {"groupId": "OG003", "value": "0.11", "spread": "0.38"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "302"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "302"}, {"groupId": "OG003", "value": "601"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "0.36"}, {"groupId": "OG001", "value": "0.13", "spread": "0.43"}, {"groupId": "OG002", "value": "-0.01", "spread": "0.40"}, {"groupId": "OG003", "value": "0.10", "spread": "0.39"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "290"}, {"groupId": "OG001", "value": "586"}, {"groupId": "OG002", "value": "302"}, {"groupId": "OG003", "value": "589"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.03", "spread": "0.34"}, {"groupId": "OG001", "value": "0.12", "spread": "0.44"}, {"groupId": "OG002", "value": "0.01", "spread": "0.38"}, {"groupId": "OG003", "value": "0.11", "spread": "0.39"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "239"}, {"groupId": "OG001", "value": "499"}, {"groupId": "OG002", "value": "255"}, {"groupId": "OG003", "value": "494"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.08", "spread": "0.38"}, {"groupId": "OG001", "value": "0.12", "spread": "0.44"}, {"groupId": "OG002", "value": "-0.02", "spread": "0.39"}, {"groupId": "OG003", "value": "0.11", "spread": "0.40"}]}]}]}, {"type": "SECONDARY", "title": "Annualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population", "description": "LOAC was defined as any of the following: \\>=6 additional reliever puffs of salbutamol/albuterol or levosalbutamol/levalbuterol in a 24-hour period (compared to baseline) on 2 consecutive days; increase in ICS \\>=4 times the dose at randomization; use of systemic corticosteroids for \\>=3 days; hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids. Annualized event rate was the total number of LOAC that occurred during the treatment period divided by the total number of participant-years treated.", "populationDescription": "Analysis was performed on ITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "LOAC per participant-year", "timeFrame": "Baseline to Week 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.972", "lowerLimit": "2.573", "upperLimit": "3.432"}, {"groupId": "OG001", "value": "1.853", "lowerLimit": "1.654", "upperLimit": "2.076"}, {"groupId": "OG002", "value": "2.965", "lowerLimit": "2.572", "upperLimit": "3.420"}, {"groupId": "OG003", "value": "1.740", "lowerLimit": "1.554", "upperLimit": "1.947"}]}]}]}, {"type": "SECONDARY", "title": "Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population", "description": "The time to first severe exacerbation was defined as follows: date of the first event - randomization date +1. For participants who had no event on or before Visit 18 (Week 52) or last contact date, the time was censored at the date of Visit 18 or the last contact date, whichever was earlier. The median time to first severe exacerbation was not estimated; therefore, the probability of severe exacerbation at Weeks 12, 24, 36, and 52, are presented as the descriptive statistics.", "populationDescription": "Analysis was performed on ITT population.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "probability of severe exacerbation", "timeFrame": "Baseline up to Week 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Probability at Week 12", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.165", "lowerLimit": "0.127", "upperLimit": "0.209"}, {"groupId": "OG001", "value": "0.094", "lowerLimit": "0.073", "upperLimit": "0.119"}, {"groupId": "OG002", "value": "0.193", "lowerLimit": "0.152", "upperLimit": "0.238"}, {"groupId": "OG003", "value": "0.137", "lowerLimit": "0.112", "upperLimit": "0.166"}]}]}, {"title": "Probability at Week 24", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.275", "lowerLimit": "0.227", "upperLimit": "0.326"}, {"groupId": "OG001", "value": "0.177", "lowerLimit": "0.148", "upperLimit": "0.208"}, {"groupId": "OG002", "value": "0.297", "lowerLimit": "0.247", "upperLimit": "0.347"}, {"groupId": "OG003", "value": "0.211", "lowerLimit": "0.180", "upperLimit": "0.243"}]}]}, {"title": "Probability at Week 36", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.364", "lowerLimit": "0.311", "upperLimit": "0.418"}, {"groupId": "OG001", "value": "0.235", "lowerLimit": "0.203", "upperLimit": "0.270"}, {"groupId": "OG002", "value": "0.376", "lowerLimit": "0.322", "upperLimit": "0.428"}, {"groupId": "OG003", "value": "0.268", "lowerLimit": "0.234", "upperLimit": "0.303"}]}]}, {"title": "Probability at Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.434", "lowerLimit": "0.378", "upperLimit": "0.489"}, {"groupId": "OG001", "value": "0.295", "lowerLimit": "0.259", "upperLimit": "0.331"}, {"groupId": "OG002", "value": "0.437", "lowerLimit": "0.382", "upperLimit": "0.491"}, {"groupId": "OG003", "value": "0.325", "lowerLimit": "0.288", "upperLimit": "0.362"}]}]}]}, {"type": "SECONDARY", "title": "Time to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population", "description": "The time to first LOAC event was defined as follows: date of the first event - first dose date +1. For participants who had no event on or before last dose date + 14 days or last contact date, the time was censored at the last dose date + 14 days or the last contact date, whichever was earlier.", "populationDescription": "Analysis was performed on ITT population.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "days", "timeFrame": "Baseline up to Week 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "110.0", "lowerLimit": "84.00", "upperLimit": "144.00"}, {"groupId": "OG001", "value": "230.0", "lowerLimit": "187.00", "upperLimit": "276.00"}, {"groupId": "OG002", "value": "102.0", "lowerLimit": "74.00", "upperLimit": "130.00"}, {"groupId": "OG003", "value": "264.0", "lowerLimit": "207.00", "upperLimit": "319.00"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in ACQ-5 Score at Weeks 2, 4, 8, 12, 36, and 52: ITT Population", "description": "The ACQ-5 has 5 questions, reflecting the top-scoring five asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of the scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "304"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "305"}, {"groupId": "OG003", "value": "615"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.52", "spread": "0.85"}, {"groupId": "OG001", "value": "-0.88", "spread": "0.91"}, {"groupId": "OG002", "value": "-0.58", "spread": "0.97"}, {"groupId": "OG003", "value": "-0.89", "spread": "0.94"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "297"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "305"}, {"groupId": "OG003", "value": "605"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.76", "spread": "0.90"}, {"groupId": "OG001", "value": "-1.07", "spread": "0.98"}, {"groupId": "OG002", "value": "-0.77", "spread": "1.01"}, {"groupId": "OG003", "value": "-1.06", "spread": "1.01"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "301"}, {"groupId": "OG001", "value": "595"}, {"groupId": "OG002", "value": "310"}, {"groupId": "OG003", "value": "593"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.94", "spread": "0.96"}, {"groupId": "OG001", "value": "-1.26", "spread": "1.03"}, {"groupId": "OG002", "value": "-1.05", "spread": "1.04"}, {"groupId": "OG003", "value": "-1.24", "spread": "1.06"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "303"}, {"groupId": "OG001", "value": "605"}, {"groupId": "OG002", "value": "312"}, {"groupId": "OG003", "value": "603"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.98", "spread": "1.00"}, {"groupId": "OG001", "value": "-1.33", "spread": "1.03"}, {"groupId": "OG002", "value": "-1.09", "spread": "1.09"}, {"groupId": "OG003", "value": "-1.35", "spread": "1.06"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "285"}, {"groupId": "OG001", "value": "583"}, {"groupId": "OG002", "value": "299"}, {"groupId": "OG003", "value": "572"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.21", "spread": "1.01"}, {"groupId": "OG001", "value": "-1.50", "spread": "1.14"}, {"groupId": "OG002", "value": "-1.22", "spread": "1.09"}, {"groupId": "OG003", "value": "-1.52", "spread": "1.09"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "236"}, {"groupId": "OG001", "value": "470"}, {"groupId": "OG002", "value": "245"}, {"groupId": "OG003", "value": "477"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.07", "spread": "1.08"}, {"groupId": "OG001", "value": "-1.50", "spread": "1.05"}, {"groupId": "OG002", "value": "-1.25", "spread": "1.05"}, {"groupId": "OG003", "value": "-1.50", "spread": "1.08"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire 7-item Version (ACQ-7) Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "The ACQ-7 has 7 questions, the first 5 questions assess the most common asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath and wheeze plus short-acting bronchodilator use, and FEV1 (pre-bronchodilator % predicted). Participants were asked to recall how their asthma had been during the previous week and to respond to each of the five symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). Clinic staff scored the FEV1% predicted on a 7-point scale. The questions were equally weighted and the ACQ-7 total score was mean of the scores of all 7 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "304"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "305"}, {"groupId": "OG003", "value": "615"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.46", "spread": "0.70"}, {"groupId": "OG001", "value": "-0.79", "spread": "0.77"}, {"groupId": "OG002", "value": "-0.50", "spread": "0.80"}, {"groupId": "OG003", "value": "-0.82", "spread": "0.81"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "297"}, {"groupId": "OG001", "value": "599"}, {"groupId": "OG002", "value": "305"}, {"groupId": "OG003", "value": "605"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.65", "spread": "0.76"}, {"groupId": "OG001", "value": "-0.94", "spread": "0.85"}, {"groupId": "OG002", "value": "-0.65", "spread": "0.85"}, {"groupId": "OG003", "value": "-0.97", "spread": "0.87"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "301"}, {"groupId": "OG001", "value": "595"}, {"groupId": "OG002", "value": "310"}, {"groupId": "OG003", "value": "593"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.81", "spread": "0.80"}, {"groupId": "OG001", "value": "-1.11", "spread": "0.90"}, {"groupId": "OG002", "value": "-0.90", "spread": "0.89"}, {"groupId": "OG003", "value": "-1.12", "spread": "0.92"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "303"}, {"groupId": "OG001", "value": "605"}, {"groupId": "OG002", "value": "312"}, {"groupId": "OG003", "value": "603"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.85", "spread": "0.83"}, {"groupId": "OG001", "value": "-1.17", "spread": "0.90"}, {"groupId": "OG002", "value": "-0.92", "spread": "0.93"}, {"groupId": "OG003", "value": "-1.20", "spread": "0.92"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "296"}, {"groupId": "OG001", "value": "590"}, {"groupId": "OG002", "value": "297"}, {"groupId": "OG003", "value": "585"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.89", "spread": "0.91"}, {"groupId": "OG001", "value": "-1.25", "spread": "0.92"}, {"groupId": "OG002", "value": "-1.01", "spread": "0.96"}, {"groupId": "OG003", "value": "-1.22", "spread": "0.96"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "285"}, {"groupId": "OG001", "value": "583"}, {"groupId": "OG002", "value": "299"}, {"groupId": "OG003", "value": "572"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.04", "spread": "0.84"}, {"groupId": "OG001", "value": "-1.32", "spread": "1.01"}, {"groupId": "OG002", "value": "-1.05", "spread": "0.94"}, {"groupId": "OG003", "value": "-1.35", "spread": "0.95"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "236"}, {"groupId": "OG001", "value": "470"}, {"groupId": "OG002", "value": "245"}, {"groupId": "OG003", "value": "477"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.91", "spread": "0.92"}, {"groupId": "OG001", "value": "-1.32", "spread": "0.91"}, {"groupId": "OG002", "value": "-1.07", "spread": "0.91"}, {"groupId": "OG003", "value": "-1.34", "spread": "0.93"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "Morning asthma symptom score was determined using AM (ante meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the night. It ranged from 0 to 4 as: 0= No asthma symptoms, slept through the night, 1= Slept well, but some complaints in the morning, no night time awakenings, 2= Woke up once because of asthma (including early awakening), 3= Woke up several times because of asthma (including early awakening), 4= Bad night, awake most of the night because of asthma.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "314"}, {"groupId": "OG001", "value": "624"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "631"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.07", "spread": "0.43"}, {"groupId": "OG001", "value": "-0.18", "spread": "0.49"}, {"groupId": "OG002", "value": "-0.09", "spread": "0.49"}, {"groupId": "OG003", "value": "-0.15", "spread": "0.50"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "623"}, {"groupId": "OG002", "value": "319"}, {"groupId": "OG003", "value": "627"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.16", "spread": "0.59"}, {"groupId": "OG001", "value": "-0.26", "spread": "0.59"}, {"groupId": "OG002", "value": "-0.16", "spread": "0.61"}, {"groupId": "OG003", "value": "-0.27", "spread": "0.64"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "620"}, {"groupId": "OG002", "value": "318"}, {"groupId": "OG003", "value": "615"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.26", "spread": "0.64"}, {"groupId": "OG001", "value": "-0.40", "spread": "0.68"}, {"groupId": "OG002", "value": "-0.25", "spread": "0.62"}, {"groupId": "OG003", "value": "-0.37", "spread": "0.70"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "306"}, {"groupId": "OG001", "value": "614"}, {"groupId": "OG002", "value": "315"}, {"groupId": "OG003", "value": "609"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.30", "spread": "0.64"}, {"groupId": "OG001", "value": "-0.45", "spread": "0.71"}, {"groupId": "OG002", "value": "-0.30", "spread": "0.69"}, {"groupId": "OG003", "value": "-0.44", "spread": "0.72"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "302"}, {"groupId": "OG001", "value": "602"}, {"groupId": "OG002", "value": "306"}, {"groupId": "OG003", "value": "592"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.35", "spread": "0.69"}, {"groupId": "OG001", "value": "-0.52", "spread": "0.76"}, {"groupId": "OG002", "value": "-0.36", "spread": "0.73"}, {"groupId": "OG003", "value": "-0.50", "spread": "0.73"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "292"}, {"groupId": "OG001", "value": "583"}, {"groupId": "OG002", "value": "299"}, {"groupId": "OG003", "value": "572"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.38", "spread": "0.69"}, {"groupId": "OG001", "value": "-0.54", "spread": "0.81"}, {"groupId": "OG002", "value": "-0.38", "spread": "0.76"}, {"groupId": "OG003", "value": "-0.56", "spread": "0.77"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "553"}, {"groupId": "OG002", "value": "286"}, {"groupId": "OG003", "value": "540"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.41", "spread": "0.71"}, {"groupId": "OG001", "value": "-0.55", "spread": "0.84"}, {"groupId": "OG002", "value": "-0.41", "spread": "0.78"}, {"groupId": "OG003", "value": "-0.60", "spread": "0.79"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "Evening asthma symptom score was determined using PM (post meridiem) symptom scoring system which evaluated participant's overall asthma symptoms experienced during the day. It ranged from 0 to 4 as: 0=very well, no asthma symptoms, 1=one episode of wheezing, cough, or breathlessness, 2=more than one episode of wheezing, cough, or breathlessness without interference of normal activities, 3=wheezing, cough, or breathlessness most of the day, which interfered to some extent with normal activities, 4=asthma very bad, unable to carry out daily activities as usual.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "624"}, {"groupId": "OG002", "value": "320"}, {"groupId": "OG003", "value": "631"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "0.45"}, {"groupId": "OG001", "value": "-0.17", "spread": "0.48"}, {"groupId": "OG002", "value": "-0.06", "spread": "0.45"}, {"groupId": "OG003", "value": "-0.16", "spread": "0.52"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "623"}, {"groupId": "OG002", "value": "319"}, {"groupId": "OG003", "value": "628"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.11", "spread": "0.59"}, {"groupId": "OG001", "value": "-0.27", "spread": "0.61"}, {"groupId": "OG002", "value": "-0.14", "spread": "0.58"}, {"groupId": "OG003", "value": "-0.29", "spread": "0.64"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "619"}, {"groupId": "OG002", "value": "318"}, {"groupId": "OG003", "value": "612"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.24", "spread": "0.64"}, {"groupId": "OG001", "value": "-0.41", "spread": "0.70"}, {"groupId": "OG002", "value": "-0.22", "spread": "0.63"}, {"groupId": "OG003", "value": "-0.40", "spread": "0.70"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "612"}, {"groupId": "OG002", "value": "314"}, {"groupId": "OG003", "value": "606"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.26", "spread": "0.66"}, {"groupId": "OG001", "value": "-0.45", "spread": "0.72"}, {"groupId": "OG002", "value": "-0.30", "spread": "0.68"}, {"groupId": "OG003", "value": "-0.46", "spread": "0.73"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "301"}, {"groupId": "OG001", "value": "596"}, {"groupId": "OG002", "value": "301"}, {"groupId": "OG003", "value": "590"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.33", "spread": "0.72"}, {"groupId": "OG001", "value": "-0.52", "spread": "0.78"}, {"groupId": "OG002", "value": "-0.36", "spread": "0.72"}, {"groupId": "OG003", "value": "-0.52", "spread": "0.73"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}, {"groupId": "OG001", "value": "576"}, {"groupId": "OG002", "value": "292"}, {"groupId": "OG003", "value": "566"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.39", "spread": "0.73"}, {"groupId": "OG001", "value": "-0.56", "spread": "0.81"}, {"groupId": "OG002", "value": "-0.39", "spread": "0.75"}, {"groupId": "OG003", "value": "-0.56", "spread": "0.80"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "274"}, {"groupId": "OG001", "value": "536"}, {"groupId": "OG002", "value": "270"}, {"groupId": "OG003", "value": "535"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.41", "spread": "0.74"}, {"groupId": "OG001", "value": "-0.57", "spread": "0.84"}, {"groupId": "OG002", "value": "-0.42", "spread": "0.75"}, {"groupId": "OG003", "value": "-0.61", "spread": "0.78"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "Participants recorded every morning on awakening the number of asthma-related nocturnal awakenings requiring use of rescue medication that occurred during the previous night.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "number of nocturnal awakenings/night", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "314"}, {"groupId": "OG001", "value": "624"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "631"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.06", "spread": "0.49"}, {"groupId": "OG001", "value": "-0.15", "spread": "0.55"}, {"groupId": "OG002", "value": "-0.04", "spread": "0.62"}, {"groupId": "OG003", "value": "-0.11", "spread": "0.67"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "623"}, {"groupId": "OG002", "value": "319"}, {"groupId": "OG003", "value": "627"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "spread": "0.61"}, {"groupId": "OG001", "value": "-0.19", "spread": "0.66"}, {"groupId": "OG002", "value": "-0.11", "spread": "0.70"}, {"groupId": "OG003", "value": "-0.20", "spread": "0.67"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "620"}, {"groupId": "OG002", "value": "318"}, {"groupId": "OG003", "value": "615"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.18", "spread": "0.65"}, {"groupId": "OG001", "value": "-0.29", "spread": "0.72"}, {"groupId": "OG002", "value": "-0.17", "spread": "0.62"}, {"groupId": "OG003", "value": "-0.24", "spread": "0.72"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "306"}, {"groupId": "OG001", "value": "614"}, {"groupId": "OG002", "value": "315"}, {"groupId": "OG003", "value": "609"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.21", "spread": "0.66"}, {"groupId": "OG001", "value": "-0.33", "spread": "0.75"}, {"groupId": "OG002", "value": "-0.18", "spread": "0.67"}, {"groupId": "OG003", "value": "-0.28", "spread": "0.73"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "302"}, {"groupId": "OG001", "value": "602"}, {"groupId": "OG002", "value": "306"}, {"groupId": "OG003", "value": "592"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.23", "spread": "0.78"}, {"groupId": "OG001", "value": "-0.36", "spread": "0.81"}, {"groupId": "OG002", "value": "-0.26", "spread": "0.65"}, {"groupId": "OG003", "value": "-0.30", "spread": "0.73"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "292"}, {"groupId": "OG001", "value": "583"}, {"groupId": "OG002", "value": "299"}, {"groupId": "OG003", "value": "572"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.25", "spread": "0.74"}, {"groupId": "OG001", "value": "-0.34", "spread": "0.81"}, {"groupId": "OG002", "value": "-0.26", "spread": "0.71"}, {"groupId": "OG003", "value": "-0.36", "spread": "0.74"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "553"}, {"groupId": "OG002", "value": "286"}, {"groupId": "OG003", "value": "540"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.24", "spread": "0.69"}, {"groupId": "OG001", "value": "-0.35", "spread": "0.88"}, {"groupId": "OG002", "value": "-0.26", "spread": "0.74"}, {"groupId": "OG003", "value": "-0.41", "spread": "0.78"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Number of Puffs of Daily Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population", "description": "Participants might administered salbutamol/albuterol or levosalbutamol/levalbuterol as reliever medication as needed during the study. The number of salbutamol/albuterol or levosalbutamol/levalbuterol inhalations were recorded daily by the participants in an electronic diary/peak expiratory flow (PEF) meter. In the case that Nebulizer solutions were used as an alternative delivery method, the nebulizer dose was converted to number of puffs as per following conversion factor: salbutamol/albuterol nebulizer solution (2.5 mg) corresponds to 4 puffs.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of puffs of reliever medication", "timeFrame": "Baseline, Weeks 2, 4, 8, 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "313"}, {"groupId": "OG001", "value": "623"}, {"groupId": "OG002", "value": "318"}, {"groupId": "OG003", "value": "630"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.21", "spread": "1.55"}, {"groupId": "OG001", "value": "-0.56", "spread": "1.96"}, {"groupId": "OG002", "value": "-0.10", "spread": "1.71"}, {"groupId": "OG003", "value": "-0.47", "spread": "1.91"}]}]}, {"title": "Change at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "312"}, {"groupId": "OG001", "value": "622"}, {"groupId": "OG002", "value": "319"}, {"groupId": "OG003", "value": "626"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.26", "spread": "2.19"}, {"groupId": "OG001", "value": "-0.68", "spread": "2.61"}, {"groupId": "OG002", "value": "-0.34", "spread": "3.42"}, {"groupId": "OG003", "value": "-0.73", "spread": "2.42"}]}]}, {"title": "Change at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "617"}, {"groupId": "OG002", "value": "314"}, {"groupId": "OG003", "value": "607"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "spread": "2.23"}, {"groupId": "OG001", "value": "-1.02", "spread": "2.86"}, {"groupId": "OG002", "value": "-0.65", "spread": "2.96"}, {"groupId": "OG003", "value": "-0.94", "spread": "2.86"}]}]}, {"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "306"}, {"groupId": "OG001", "value": "610"}, {"groupId": "OG002", "value": "310"}, {"groupId": "OG003", "value": "603"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.52", "spread": "2.28"}, {"groupId": "OG001", "value": "-1.23", "spread": "3.03"}, {"groupId": "OG002", "value": "-0.89", "spread": "3.06"}, {"groupId": "OG003", "value": "-1.08", "spread": "2.72"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "294"}, {"groupId": "OG001", "value": "588"}, {"groupId": "OG002", "value": "300"}, {"groupId": "OG003", "value": "582"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.77", "spread": "2.60"}, {"groupId": "OG001", "value": "-1.27", "spread": "3.05"}, {"groupId": "OG002", "value": "-0.99", "spread": "3.21"}, {"groupId": "OG003", "value": "-1.15", "spread": "2.83"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "285"}, {"groupId": "OG001", "value": "564"}, {"groupId": "OG002", "value": "287"}, {"groupId": "OG003", "value": "558"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.99", "spread": "2.49"}, {"groupId": "OG001", "value": "-1.30", "spread": "2.99"}, {"groupId": "OG002", "value": "-1.06", "spread": "3.57"}, {"groupId": "OG003", "value": "-1.23", "spread": "3.01"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "270"}, {"groupId": "OG001", "value": "522"}, {"groupId": "OG002", "value": "265"}, {"groupId": "OG003", "value": "521"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.90", "spread": "2.58"}, {"groupId": "OG001", "value": "-1.45", "spread": "3.33"}, {"groupId": "OG002", "value": "-1.12", "spread": "3.64"}, {"groupId": "OG003", "value": "-1.39", "spread": "2.97"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in AQLQ (S) Self-Administered Global Score at Weeks 12, 36, and 52: ITT Population", "description": "The AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that are most important to participants with asthma. The AQLQ comprises of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item is scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire are averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Weeks 12, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "286"}, {"groupId": "OG001", "value": "573"}, {"groupId": "OG002", "value": "308"}, {"groupId": "OG003", "value": "586"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.90", "spread": "0.97"}, {"groupId": "OG001", "value": "1.09", "spread": "1.03"}, {"groupId": "OG002", "value": "0.94", "spread": "1.01"}, {"groupId": "OG003", "value": "1.09", "spread": "1.09"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "271"}, {"groupId": "OG001", "value": "554"}, {"groupId": "OG002", "value": "295"}, {"groupId": "OG003", "value": "548"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.05", "spread": "1.08"}, {"groupId": "OG001", "value": "1.26", "spread": "1.17"}, {"groupId": "OG002", "value": "1.08", "spread": "1.16"}, {"groupId": "OG003", "value": "1.33", "spread": "1.15"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "465"}, {"groupId": "OG002", "value": "243"}, {"groupId": "OG003", "value": "459"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "spread": "1.12"}, {"groupId": "OG001", "value": "1.28", "spread": "1.16"}, {"groupId": "OG002", "value": "1.02", "spread": "1.10"}, {"groupId": "OG003", "value": "1.34", "spread": "1.16"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Weeks 12, 24, 36, and 52: ITT Population", "description": "EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).", "populationDescription": "Analysis was performed on ITT population. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Weeks 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "317"}, {"groupId": "OG001", "value": "631"}, {"groupId": "OG002", "value": "321"}, {"groupId": "OG003", "value": "633"}]}], "classes": [{"title": "Single Index: Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "567"}, {"groupId": "OG002", "value": "301"}, {"groupId": "OG003", "value": "576"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "spread": "0.17"}, {"groupId": "OG001", "value": "0.09", "spread": "0.18"}, {"groupId": "OG002", "value": "0.08", "spread": "0.18"}, {"groupId": "OG003", "value": "0.09", "spread": "0.18"}]}]}, {"title": "Single Index: Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "552"}, {"groupId": "OG002", "value": "292"}, {"groupId": "OG003", "value": "559"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "spread": "0.17"}, {"groupId": "OG001", "value": "0.09", "spread": "0.17"}, {"groupId": "OG002", "value": "0.08", "spread": "0.18"}, {"groupId": "OG003", "value": "0.08", "spread": "0.20"}]}]}, {"title": "Single Index: Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "264"}, {"groupId": "OG001", "value": "548"}, {"groupId": "OG002", "value": "290"}, {"groupId": "OG003", "value": "537"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.08", "spread": "0.19"}, {"groupId": "OG001", "value": "0.09", "spread": "0.20"}, {"groupId": "OG002", "value": "0.10", "spread": "0.18"}, {"groupId": "OG003", "value": "0.09", "spread": "0.20"}]}]}, {"title": "Single Index: Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "220"}, {"groupId": "OG001", "value": "457"}, {"groupId": "OG002", "value": "238"}, {"groupId": "OG003", "value": "448"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "spread": "0.20"}, {"groupId": "OG001", "value": "0.10", "spread": "0.19"}, {"groupId": "OG002", "value": "0.08", "spread": "0.19"}, {"groupId": "OG003", "value": "0.10", "spread": "0.20"}]}]}, {"title": "VAS Score: Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "280"}, {"groupId": "OG001", "value": "567"}, {"groupId": "OG002", "value": "301"}, {"groupId": "OG003", "value": "576"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.69", "spread": "17.43"}, {"groupId": "OG001", "value": "11.10", "spread": "18.90"}, {"groupId": "OG002", "value": "6.39", "spread": "20.42"}, {"groupId": "OG003", "value": "9.80", "spread": "19.56"}]}]}, {"title": "VAS Score: Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "275"}, {"groupId": "OG001", "value": "552"}, {"groupId": "OG002", "value": "292"}, {"groupId": "OG003", "value": "559"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.33", "spread": "17.58"}, {"groupId": "OG001", "value": "11.44", "spread": "18.48"}, {"groupId": "OG002", "value": "8.59", "spread": "20.37"}, {"groupId": "OG003", "value": "9.21", "spread": "19.61"}]}]}, {"title": "VAS Score: Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "264"}, {"groupId": "OG001", "value": "548"}, {"groupId": "OG002", "value": "290"}, {"groupId": "OG003", "value": "537"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.70", "spread": "18.24"}, {"groupId": "OG001", "value": "11.61", "spread": "19.09"}, {"groupId": "OG002", "value": "9.31", "spread": "20.09"}, {"groupId": "OG003", "value": "11.41", "spread": "19.40"}]}]}, {"title": "VAS Score: Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "220"}, {"groupId": "OG001", "value": "457"}, {"groupId": "OG002", "value": "238"}, {"groupId": "OG003", "value": "448"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.35", "spread": "18.51"}, {"groupId": "OG001", "value": "12.98", "spread": "18.71"}, {"groupId": "OG002", "value": "9.52", "spread": "20.81"}, {"groupId": "OG003", "value": "11.90", "spread": "19.60"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12, 24, 36, and 52: ITT Population", "description": "The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. And the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.", "populationDescription": "Analysis was performed on ITT population; 29 participants in Japan who received an incorrectly translated HADS questionnaire were excluded. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Weeks 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "311"}, {"groupId": "OG001", "value": "621"}, {"groupId": "OG002", "value": "317"}, {"groupId": "OG003", "value": "624"}]}], "classes": [{"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "274"}, {"groupId": "OG001", "value": "551"}, {"groupId": "OG002", "value": "297"}, {"groupId": "OG003", "value": "569"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.11", "spread": "5.29"}, {"groupId": "OG001", "value": "-1.91", "spread": "5.65"}, {"groupId": "OG002", "value": "-1.55", "spread": "6.11"}, {"groupId": "OG003", "value": "-1.98", "spread": "5.89"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "270"}, {"groupId": "OG001", "value": "537"}, {"groupId": "OG002", "value": "286"}, {"groupId": "OG003", "value": "552"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.17", "spread": "5.71"}, {"groupId": "OG001", "value": "-1.93", "spread": "5.97"}, {"groupId": "OG002", "value": "-1.73", "spread": "6.36"}, {"groupId": "OG003", "value": "-1.88", "spread": "6.39"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "260"}, {"groupId": "OG001", "value": "535"}, {"groupId": "OG002", "value": "286"}, {"groupId": "OG003", "value": "532"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.52", "spread": "5.89"}, {"groupId": "OG001", "value": "-2.02", "spread": "6.34"}, {"groupId": "OG002", "value": "-2.67", "spread": "6.80"}, {"groupId": "OG003", "value": "-2.13", "spread": "6.67"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "213"}, {"groupId": "OG001", "value": "443"}, {"groupId": "OG002", "value": "234"}, {"groupId": "OG003", "value": "438"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.00", "spread": "6.29"}, {"groupId": "OG001", "value": "-2.36", "spread": "6.28"}, {"groupId": "OG002", "value": "-1.86", "spread": "6.79"}, {"groupId": "OG003", "value": "-2.17", "spread": "7.04"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in 22-Item Sino Nasal Outcome Test (SNOT-22) Score at Weeks 12, 24, 36, and 52: ITT Population With Bilateral Nasal Polyposis/Chronic Rhinosinusitis", "description": "The SNOT-22 is a validated measure of health related quality of life in sinonasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.", "populationDescription": "Analysis was performed on ITT population with bilateral nasal polyposis/chronic rhinosinusitis. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Weeks 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "126"}, {"groupId": "OG002", "value": "70"}, {"groupId": "OG003", "value": "123"}]}], "classes": [{"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "113"}, {"groupId": "OG002", "value": "61"}, {"groupId": "OG003", "value": "102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.82", "spread": "17.19"}, {"groupId": "OG001", "value": "-13.55", "spread": "16.85"}, {"groupId": "OG002", "value": "-11.30", "spread": "16.11"}, {"groupId": "OG003", "value": "-16.07", "spread": "20.54"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "52"}, {"groupId": "OG001", "value": "111"}, {"groupId": "OG002", "value": "58"}, {"groupId": "OG003", "value": "102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.21", "spread": "17.10"}, {"groupId": "OG001", "value": "-14.68", "spread": "18.77"}, {"groupId": "OG002", "value": "-9.55", "spread": "16.04"}, {"groupId": "OG003", "value": "-17.41", "spread": "20.81"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "111"}, {"groupId": "OG002", "value": "57"}, {"groupId": "OG003", "value": "100"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.10", "spread": "19.03"}, {"groupId": "OG001", "value": "-15.23", "spread": "18.20"}, {"groupId": "OG002", "value": "-8.51", "spread": "20.36"}, {"groupId": "OG003", "value": "-18.86", "spread": "21.34"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "89"}, {"groupId": "OG002", "value": "49"}, {"groupId": "OG003", "value": "85"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-6.95", "spread": "17.10"}, {"groupId": "OG001", "value": "-15.78", "spread": "17.72"}, {"groupId": "OG002", "value": "-9.98", "spread": "18.01"}, {"groupId": "OG003", "value": "-19.81", "spread": "22.39"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, Ages 12+ (RQLQ[S]+12) Score at Weeks 12, 24, 36, and 52: ITT Population With Comorbid Allergic Rhinitis", "description": "RQLQ(S)+12 is a self-administered questionnaire with standardized activities developed to measure health-related quality of life signs and symptoms that are most problematic in those 12 to 75 years of age, as a result of perennial or seasonal allergic rhinitis. There are 28 items on RQLQ(S) in 7 domains: activities (3 items), sleep (3 items), non-nose/eye symptoms (7 items), practical problems (3 items), nasal symptoms (4 items), eye symptoms (4 items) and emotional (4 items). RQLQ(S)+12 responses are based on 7-point likert scale with responses ranging from 0 (not troubled) to 6 (extremely troubled). Individual items within RQLQ(S)+12 are equally weighted. The overall score is calculated as the mean score of all items. Higher scores indicated more health-related quality of life impairment (lower scores better).", "populationDescription": "Analysis was performed on ITT population with comorbid allergic rhinitis. Here 'Number analyzed' signifies number of participants with available data for specified category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline, Weeks 12, 24, 36, and 52", "groups": [{"id": "OG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}, {"id": "OG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "194"}, {"groupId": "OG001", "value": "390"}, {"groupId": "OG002", "value": "214"}, {"groupId": "OG003", "value": "409"}]}], "classes": [{"title": "Change at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "167"}, {"groupId": "OG001", "value": "332"}, {"groupId": "OG002", "value": "192"}, {"groupId": "OG003", "value": "348"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "spread": "0.98"}, {"groupId": "OG001", "value": "-0.70", "spread": "0.99"}, {"groupId": "OG002", "value": "-0.44", "spread": "1.05"}, {"groupId": "OG003", "value": "-0.64", "spread": "1.06"}]}]}, {"title": "Change at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "164"}, {"groupId": "OG001", "value": "322"}, {"groupId": "OG002", "value": "182"}, {"groupId": "OG003", "value": "342"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "spread": "0.92"}, {"groupId": "OG001", "value": "-0.73", "spread": "1.09"}, {"groupId": "OG002", "value": "-0.54", "spread": "1.10"}, {"groupId": "OG003", "value": "-0.60", "spread": "1.10"}]}]}, {"title": "Change at Week 36", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "158"}, {"groupId": "OG001", "value": "323"}, {"groupId": "OG002", "value": "184"}, {"groupId": "OG003", "value": "332"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.56", "spread": "0.96"}, {"groupId": "OG001", "value": "-0.78", "spread": "1.15"}, {"groupId": "OG002", "value": "-0.58", "spread": "1.20"}, {"groupId": "OG003", "value": "-0.75", "spread": "1.12"}]}]}, {"title": "Change at Week 52", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "263"}, {"groupId": "OG002", "value": "149"}, {"groupId": "OG003", "value": "274"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.41", "spread": "0.97"}, {"groupId": "OG001", "value": "-0.90", "spread": "1.17"}, {"groupId": "OG002", "value": "-0.47", "spread": "1.33"}, {"groupId": "OG003", "value": "-0.76", "spread": "1.13"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 64) or entry in the LTS12551 open-label extension study regardless of seriousness or relationship to investigational product.", "description": "Reported AEs are treatment emergent AEs that developed/worsened during 'treatment-emergent period' (from first dose of IMP until 98 days after last dose of IMP or entry in the LTS12551 study). Safety population:all participants who received at least 1 dose or part of a dose of IMP, analyzed according to treatment that participants actually received.", "eventGroups": [{"id": "EG000", "title": "Placebo (for Dupilumab 200 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. 2 participants were excluded, who were randomized to this arm but received single injection of Dupilumab 200 mg q2w and 300 mg q2w, respectively.", "deathsNumAffected": 3, "deathsNumAtRisk": 313, "seriousNumAffected": 26, "seriousNumAtRisk": 313, "otherNumAffected": 185, "otherNumAtRisk": 313}, {"id": "EG001", "title": "Dupilumab 200 mg q2w", "description": "2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. 2 participants were included, who were randomized to Placebo (for Dupilumab 200 mg) arm and Dupilumab 300 mg arm, respectively but both received Dupilumab 200 mg.", "deathsNumAffected": 1, "deathsNumAtRisk": 631, "seriousNumAffected": 51, "seriousNumAtRisk": 631, "otherNumAffected": 363, "otherNumAtRisk": 631}, {"id": "EG002", "title": "Placebo (for Dupilumab 300 mg) q2w", "description": "2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.", "deathsNumAffected": 0, "deathsNumAtRisk": 321, "seriousNumAffected": 28, "seriousNumAtRisk": 321, "otherNumAffected": 197, "otherNumAtRisk": 321}, {"id": "EG003", "title": "Dupilumab 300 mg q2w", "description": "2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines (second or third controller therapy). Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. 1 participant was excluded, who was randomized to this arm but received single injection of Dupilumab 200 mg q2w. 1 participant was included, who was randomized to Placebo (for Dupilumab 200 mg) arm but received Dupilumab 300 mg.", "deathsNumAffected": 5, "deathsNumAtRisk": 632, "seriousNumAffected": 56, "seriousNumAtRisk": 632, "otherNumAffected": 378, "otherNumAtRisk": 632}], "seriousEvents": [{"term": "Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Atypical pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 632}]}, {"term": "Capnocytophaga infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Clostridium difficile colitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Hepatitis A", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Hepatitis C", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Mastoiditis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Medical device site infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 632}]}, {"term": "Post procedural cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Pyelonephritis chronic", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Tick-borne viral encephalitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Adenocarcinoma of colon", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Anaplastic thyroid cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Clear cell renal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Dysplastic naevus", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Haemangioblastoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 632}]}, {"term": "Papillary thyroid cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Rectal adenocarcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Small intestine carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Eosinophilia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Neutropenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Anaphylactic shock", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Primary hyperaldosteronism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Adjustment disorder with depressed mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Completed suicide", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Major depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Retinal detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Retinal tear", "organSystem": "Eye disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 632}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Atrioventricular block second degree", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 632}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Ischaemic cardiomyopathy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Tachyarrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Thrombophlebitis superficial", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 7, "numAtRisk": 632}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Eosinophilic pneumonia chronic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Interstitial lung disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Laryngeal oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Noninfective bronchitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Pleurisy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Pneumothorax spontaneous", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Respiratory depression", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Abdominal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Diverticular perforation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Diverticulum", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Diverticulum intestinal", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Enteritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Gastric volvulus", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Hiatus hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Impaired gastric emptying", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Large intestine polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Oesophageal motility disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Oesophageal ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Strangulated umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 632}]}, {"term": "Cholecystitis chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Portal vein thrombosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Costochondritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 632}]}, {"term": "Pathological fracture", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Polychondritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Renal infarct", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Urinary incontinence", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Abortion threatened", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Ectopic pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Cervical cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Sickle cell anaemia", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Impaired healing", "organSystem": "General disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Injection site inflammation", "organSystem": "General disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Injection site oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Concussion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Facial bones fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 632}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Fibula fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Ligament rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Multiple injuries", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Pneumothorax traumatic", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Post-traumatic pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Postoperative thoracic procedure complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Procedural pneumothorax", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Radius fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Spinal compression fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Spinal cord injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Ulna fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Upper limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Wrist fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 632}]}, {"term": "Pregnancy of partner", "organSystem": "Social circumstances", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Victim of sexual abuse", "organSystem": "Social circumstances", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}, {"term": "Device material issue", "organSystem": "Product Issues", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 632}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 47, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 73, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 43, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 70, "numAtRisk": 632}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 36, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 22, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 38, "numAtRisk": 632}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 36, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 29, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 26, "numAtRisk": 632}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 37, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 70, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 48, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 77, "numAtRisk": 632}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 20, "numAtRisk": 632}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 60, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 121, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 64, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 112, "numAtRisk": 632}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 47, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 25, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 40, "numAtRisk": 632}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 15, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 18, "numAtRisk": 632}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 25, "numAtRisk": 632}]}, {"term": "Injection site erythema", "organSystem": "General disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 76, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 22, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 98, "numAtRisk": 632}]}, {"term": "Injection site oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 40, "numAtRisk": 632}]}, {"term": "Accidental overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 313}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 631}, {"groupId": "EG002", "numAffected": 16, "numAtRisk": 321}, {"groupId": "EG003", "numAffected": 34, "numAtRisk": 632}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "Sanofi", "email": "Contact-US@sanofi.com", "phone": "800-633-1610", "phoneExt": "1#"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-05-26", "uploadDate": "2018-07-27T19:02", "filename": "Prot_000.pdf", "size": 4333102}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-05-18", "uploadDate": "2018-07-27T19:03", "filename": "SAP_001.pdf", "size": 1511621}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "Diameter", "relevance": "HIGH"}, {"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}]}}, "hasResults": true}